{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:19:51Z","timestamp":1788848391182,"version":"build-2803163510"},"reference-count":417,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2019\/15873-6"],"award-info":[{"award-number":["2019\/15873-6"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2025\/00196-0"],"award-info":[{"award-number":["2025\/00196-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Sao Paulo Research Foundation","doi-asserted-by":"publisher","award":["2021\/11240-9"],"award-info":[{"award-number":["2021\/11240-9"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Epigenetic regulation, including DNA methylation, histone modifications, non-coding RNAs, and higher-order chromatin remodeling, plays a central role in the biology of neuroendocrine neoplasms (NENs). Advances in high-throughput profiling have uncovered epigenetic alterations across pheochromocytomas\/paragangliomas (PPGLs), gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), lung neuroendocrine neoplasms (LNENs), medullary thyroid carcinoma (MTC), and pituitary NETs (PitNETs). These alterations converge on pathways governing cell cycle control, telomere maintenance, hypoxia signaling, epithelial\u2013mesenchymal transition, and chromatin architecture. Importantly, epigenetic signatures not only mirror genetic backgrounds (eg, SDHx, MEN1, ATRX, RET) but also provide independent layers of prognostic and predictive information. Distinct methylation profiles, histone modification patterns, and deregulated microRNA\/long non-coding RNA networks have been consistently linked to tumor aggressiveness, metastatic potential, and therapeutic resistance. The clinical translation of these insights is rapidly evolving. Methylation-based classifiers and circulating epigenetic markers are emerging as promising tools for early diagnosis, risk stratification, and longitudinal monitoring. Moreover, epigenetic pathways represent attractive therapeutic targets, with DNA methyltransferase inhibitors, histone deacetylase inhibitors, and RNA-modifying enzyme modulators under active investigation. However, significant challenges remain, including methodological heterogeneity, small or retrospective cohorts, and the limited functional validation of candidate biomarkers. Future priorities include prospective multi-institutional validation, integration of epigenomics with other molecular layers in multidimensional classifiers, and the application of spatial and single cell approaches to resolve intra-tumoral heterogeneity. Ultimately, epigenetic research has redefined our understanding of NEN pathogenesis and progression, positioning the epigenome as a promising frontier in precision oncology. Through robust validation, epigenetic biomarkers and therapies may transform the clinical management of NENs.<\/jats:p>","DOI":"10.1210\/endrev\/bnag005","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:42:06Z","timestamp":1770986526000},"page":"422-467","source":"Crossref","is-referenced-by-count":3,"title":["Epigenetics and disease progression in neuroendocrine neoplasms"],"prefix":"10.1210","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1830-2587","authenticated-orcid":false,"given":"Eduardo C","family":"Lobato","sequence":"first","affiliation":[{"name":"Unidade de Adrenal, Laborat\u00f3rio de Endocrinologia Molecular e Celular LIM25, Divis\u00e3o de Endocrinologia e Metabologia, Hospital das Cl\u00ednicas, Faculdade de Medicina da Universidade de S\u00e3o Paulo , S\u00e3o Paulo 01246-903 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0445-4445","authenticated-orcid":false,"given":"Andre F","family":"Lafranchi","sequence":"additional","affiliation":[{"name":"Unidade de Adrenal, Laborat\u00f3rio de Endocrinologia Molecular e Celular LIM25, Divis\u00e3o de Endocrinologia e Metabologia, Hospital das Cl\u00ednicas, Faculdade de Medicina da Universidade de S\u00e3o Paulo , S\u00e3o Paulo 01246-903 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5340-432X","authenticated-orcid":false,"given":"Felipe","family":"Freitas-Castro","sequence":"additional","affiliation":[{"name":"Unidade de Adrenal, Laborat\u00f3rio de Endocrinologia Molecular e Celular LIM25, Divis\u00e3o de Endocrinologia e Metabologia, Hospital das Cl\u00ednicas, Faculdade de Medicina da Universidade de S\u00e3o Paulo , S\u00e3o Paulo 01246-903 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4097-3029","authenticated-orcid":false,"given":"Gustavo F C","family":"Fagundes","sequence":"additional","affiliation":[{"name":"Unidade de Adrenal, Laborat\u00f3rio de Endocrinologia Molecular e Celular LIM25, Divis\u00e3o de Endocrinologia e Metabologia, Hospital das Cl\u00ednicas, Faculdade de Medicina da Universidade de S\u00e3o Paulo , S\u00e3o Paulo 01246-903 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6363-0016","authenticated-orcid":false,"given":"Bekim","family":"Sadikovic","sequence":"additional","affiliation":[{"name":"Verspeeten Clinical Genome Centre, London Health Sciences Centre , London, ON N6A 5W9 ,","place":["Canada"]},{"name":"Department of Pathology and Laboratory Medicine, Western University , London, ON N6A 5C1 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0764-8681","authenticated-orcid":false,"given":"Kate E","family":"Lines","sequence":"additional","affiliation":[{"name":"School of Biological and Medical Sciences, Faculty of Health, Science and Technology, Oxford Brookes University , Oxford OX3 0BP ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2957-6148","authenticated-orcid":false,"given":"Madson Q","family":"Almeida","sequence":"additional","affiliation":[{"name":"Unidade de Adrenal, Laborat\u00f3rio de Endocrinologia Molecular e Celular LIM25, Divis\u00e3o de Endocrinologia e Metabologia, Hospital das Cl\u00ednicas, Faculdade de Medicina da Universidade de S\u00e3o Paulo , S\u00e3o Paulo 01246-903 ,","place":["Brazil"]},{"name":"Unidade de Oncologia End\u00f3crina, Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo (ICESP), Faculdade de Medicina da Universidade de S\u00e3o Paulo , S\u00e3o Paulo 01246-000 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"2","key":"2026071419565929100_bnag005-B1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1210\/endrev\/bnz004","article-title":"Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms","volume":"41","author":"Hofland","year":"2020","journal-title":"Endocr Rev"},{"issue":"1","key":"2026071419565929100_bnag005-B2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"issue":"2","key":"2026071419565929100_bnag005-B3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41574-020-00458-x","article-title":"Diagnostic and therapeutic advances in neuroendocrine tumours","volume":"17","author":"Caplin","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2026071419565929100_bnag005-B4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"issue":"3","key":"2026071419565929100_bnag005-B5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MED.0000000000000330","article-title":"Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials","volume":"24","author":"Roman-Gonzalez","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"5","key":"2026071419565929100_bnag005-B6","doi-asserted-by":"crossref","first-page":"e1937","DOI":"10.1210\/clinem\/dgaa982","article-title":"Metastatic pheochromocytomas and abdominal paragangliomas","volume":"106","author":"Granberg","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026071419565929100_bnag005-B7","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1038\/ncomms7140","article-title":"Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas","volume":"6","author":"Fishbein","year":"2015","journal-title":"Nat Commun"},{"issue":"9","key":"2026071419565929100_bnag005-B8","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026071419565929100_bnag005-B9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"2026071419565929100_bnag005-B10","doi-asserted-by":"crossref","first-page":"101977","DOI":"10.1016\/j.beem.2025.101977","article-title":"Systemic therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"39","author":"Fischer","year":"2025","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"2026071419565929100_bnag005-B11","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J Clin Endocrinol Metabol"},{"issue":"5","key":"2026071419565929100_bnag005-B12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.amjoto.2013.03.010","article-title":"Malignant head and neck paragangliomas: treatment efficacy and prognostic indicators","volume":"34","author":"Sethi","year":"2013","journal-title":"Am J Otolaryngol"},{"issue":"3","key":"2026071419565929100_bnag005-B13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.surg.2018.05.001","article-title":"A clinical prediction model to estimate the metastatic potential of pheochromocytoma\/paraganglioma: ASES score","volume":"164","author":"Cho","year":"2018","journal-title":"Surgery"},{"issue":"10","key":"2026071419565929100_bnag005-B14","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/j.1365-2362.2011.02518.x","article-title":"Metastatic pheochromocytoma: does the size and age matter?","volume":"41","author":"Zelinka","year":"2011","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"2026071419565929100_bnag005-B15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/0004563217739931","article-title":"Clinical evaluation and treatment of phaeochromocytoma","volume":"55","author":"Davison","year":"2018","journal-title":"Ann Clin Biochem"},{"issue":"11","key":"2026071419565929100_bnag005-B16","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur J Cancer"},{"issue":"12","key":"2026071419565929100_bnag005-B17","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab163","article-title":"Dopamine-secreting pheochromocytoma and paraganglioma","volume":"5","author":"Miyamoto","year":"2021","journal-title":"J Endocr Soc"},{"issue":"3","key":"2026071419565929100_bnag005-B18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/ERC-13-0494","article-title":"Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma","volume":"21","author":"Kimura","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"2026071419565929100_bnag005-B19","doi-asserted-by":"crossref","first-page":"e0187398","DOI":"10.1371\/journal.pone.0187398","article-title":"Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma","volume":"12","author":"Koh","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"2026071419565929100_bnag005-B20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"Nolting","year":"2022","journal-title":"Endocr Rev"},{"issue":"10","key":"2026071419565929100_bnag005-B21","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1210\/clinem\/dgaf259","article-title":"Approach to the patient with metastatic pheochromocytoma and paraganglioma","volume":"110","author":"Alkaissi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026071419565929100_bnag005-B22","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1210\/er.2018-00160","article-title":"Genetics and epigenetics of gastroenteropancreatic neuroendocrine neoplasms","volume":"40","author":"Mafficini","year":"2019","journal-title":"Endocr Rev"},{"issue":"2","key":"2026071419565929100_bnag005-B23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12022-024-09807-2","article-title":"Molecular classification of gastrointestinal and pancreatic neuroendocrine neoplasms: are we ready for that?","volume":"35","author":"Uccella","year":"2024","journal-title":"Endocr Pathol"},{"issue":"33","key":"2026071419565929100_bnag005-B24","doi-asserted-by":"crossref","first-page":"e21682","DOI":"10.1097\/MD.0000000000021682","article-title":"An 11-year retrospective study: clinicopathological and survival analysis of gastro-entero-pancreatic neuroendocrine neoplasm","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"2026071419565929100_bnag005-B25","doi-asserted-by":"crossref","first-page":"R315","DOI":"10.1530\/ERC-17-0012","article-title":"Genetic and epigenetic drivers of neuroendocrine tumours (NET)","volume":"24","author":"Di Domenico","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"2026071419565929100_bnag005-B26","doi-asserted-by":"crossref","first-page":"101131","DOI":"10.1016\/j.currproblcancer.2024.101131","article-title":"Gastroenteropancreatic neuroendocrine tumors: epigenetic landscape and clinical implications","volume":"52","author":"McMurry","year":"2024","journal-title":"Curr Probl Cancer"},{"issue":"2","key":"2026071419565929100_bnag005-B27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/MPA.0000000000001981","article-title":"Clinicopathological characteristics of gastroenteropancreatic neuroendocrine tumors: 10 years of experience from a single center","volume":"51","author":"\u015eent\u00fcrk","year":"2022","journal-title":"Pancreas"},{"issue":"4","key":"2026071419565929100_bnag005-B28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/archsurg.142.4.347","article-title":"Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005","volume":"142","author":"Vagefi","year":"2007","journal-title":"Arch Surg"},{"issue":"1","key":"2026071419565929100_bnag005-B29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/OP-25-00133","article-title":"Symptom management for well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline","volume":"22","author":"Perez","year":"2026","journal-title":"JCO Oncol Pract"},{"issue":"4","key":"2026071419565929100_bnag005-B30","doi-asserted-by":"crossref","first-page":"e70001","DOI":"10.1111\/jne.70001","article-title":"Incidence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): an updated systematic review of population-based reports from 2010 to 2023","volume":"37","author":"Nordstrand","year":"2025","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"2026071419565929100_bnag005-B31","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026071419565929100_bnag005-B32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41379-021-00943-2","article-title":"Lung neuroendocrine neoplasms: recent progress and persistent challenges","volume":"35","author":"Rekhtman","year":"2022","journal-title":"Mod Pathol"},{"issue":"3","key":"2026071419565929100_bnag005-B33","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO classification of lung tumors: impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2026071419565929100_bnag005-B34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41571-022-00696-0","article-title":"Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies","volume":"20","author":"Kawasaki","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"2026071419565929100_bnag005-B35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJM197308302890901","article-title":"C-cell hyperplasia preceding medullary thyroid carcinoma","volume":"289","author":"Wolfe","year":"1973","journal-title":"N Engl J Med"},{"issue":"5","key":"2026071419565929100_bnag005-B36","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1210\/endrev\/bnad013","article-title":"Medullary thyroid cancer: updates and challenges","volume":"44","author":"Gild","year":"2023","journal-title":"Endocr Rev"},{"issue":"1","key":"2026071419565929100_bnag005-B37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12022-023-09753-5","article-title":"Update on C-cell neuroendocrine neoplasm: prognostic and predictive histopathologic and molecular features of medullary thyroid carcinoma","volume":"34","author":"Jung","year":"2023","journal-title":"Endocr Pathol"},{"issue":"3","key":"2026071419565929100_bnag005-B38","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/cncr.29761","article-title":"Surgery for lymph node metastases of medullary thyroid carcinoma: a review","volume":"122","author":"Jin","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"2026071419565929100_bnag005-B39","doi-asserted-by":"crossref","first-page":"e240077","DOI":"10.1530\/EO-24-0077","article-title":"Overview of management and therapeutic advances in medullary thyroid cancer","volume":"5","author":"Jara","year":"2025","journal-title":"Endocr Oncol"},{"issue":"9","key":"2026071419565929100_bnag005-B40","doi-asserted-by":"crossref","first-page":"100244","DOI":"10.1016\/j.modpat.2023.100244","article-title":"Medullary thyroid carcinomas classified according to the international medullary carcinoma grading system and a surveillance, epidemiology, and end results-based metastatic risk score: a correlation with genetic profile and angioinvasion","volume":"36","author":"Torricelli","year":"2023","journal-title":"Mod Pathol"},{"issue":"3","key":"2026071419565929100_bnag005-B41","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3171\/2014.5.JNS131819","article-title":"Descriptive epidemiology of pituitary tumors in the United States, 2004\u20132009","volume":"121","author":"Gittleman","year":"2014","journal-title":"J Neurosurg"},{"key":"2026071419565929100_bnag005-B42","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fendo.2019.00290","article-title":"The epigenomics of pituitary adenoma","volume":"10","author":"Hauser","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2026071419565929100_bnag005-B43","doi-asserted-by":"crossref","first-page":"e220291","DOI":"10.1530\/JOE-22-0291","article-title":"Pituitary tumours: molecular and genetic aspects","volume":"257","author":"De Sousa","year":"2023","journal-title":"J Endocrinol"},{"issue":"4","key":"2026071419565929100_bnag005-B44","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1530\/EJE-21-0075","article-title":"Clinical and genetic characteristics in patients under 30 years with sporadic pituitary adenomas","volume":"185","author":"Mart\u00ednez de LaPiscina","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"2026071419565929100_bnag005-B45","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/neuonc\/noaf109","article-title":"DNA methylation profiling of pituitary neuroendocrine tumors identifies distinct clinical and pathological subtypes based on epigenetic differentiation","volume":"27","author":"Belakhoua","year":"2025","journal-title":"Neuro Oncol"},{"issue":"8","key":"2026071419565929100_bnag005-B46","doi-asserted-by":"crossref","first-page":"102841","DOI":"10.1016\/j.arcmed.2023.102841","article-title":"Primary pituitary carcinoids do not exist: a reappraisal in the era of pituitary neuroendocrine tumours","volume":"54","author":"Armeni","year":"2023","journal-title":"Arch Med Res"},{"issue":"1","key":"2026071419565929100_bnag005-B47","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","article-title":"Overview of the 2022 WHO classification of pituitary tumors","volume":"33","author":"Asa","year":"2022","journal-title":"Endocr Pathol"},{"issue":"1","key":"2026071419565929100_bnag005-B48","first-page":"9","article-title":"X inactivation, differentiation, and DNA methylation","volume":"14","author":"Riggs","year":"1975","journal-title":"Cytogenet Cell Genet"},{"issue":"4173","key":"2026071419565929100_bnag005-B49","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1126\/science.187.4173.226","article-title":"DNA modification mechanisms and gene activity during development","volume":"187","author":"Holliday","year":"1975","journal-title":"Science"},{"issue":"8","key":"2026071419565929100_bnag005-B50","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrg.2016.59","article-title":"The molecular hallmarks of epigenetic control","volume":"17","author":"Allis","year":"2016","journal-title":"Nat Rev Genet"},{"issue":"10","key":"2026071419565929100_bnag005-B51","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.jmb.2017.02.008","article-title":"Dynamics and context-dependent roles of DNA methylation","volume":"429","author":"Ambrosi","year":"2017","journal-title":"J Mol Biol"},{"issue":"1","key":"2026071419565929100_bnag005-B52","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1101\/gad.947102","article-title":"DNA methylation patterns and epigenetic memory","volume":"16","author":"Bird","year":"2002","journal-title":"Genes Dev"},{"issue":"1","key":"2026071419565929100_bnag005-B53","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1146\/annurev-genom-090613-094245","article-title":"Mendelian disorders of the epigenetic machinery: tipping the balance of chromatin states","volume":"15","author":"Fahrner","year":"2014","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"23","key":"2026071419565929100_bnag005-B54","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1242\/dev.068320","article-title":"Fifty years of X-inactivation research","volume":"138","author":"Gendrel","year":"2011","journal-title":"Development"},{"issue":"4","key":"2026071419565929100_bnag005-B55","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"issue":"7143","key":"2026071419565929100_bnag005-B56","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nature05918","article-title":"Stability and flexibility of epigenetic gene regulation in mammalian development","volume":"447","author":"Reik","year":"2007","journal-title":"Nature"},{"issue":"7","key":"2026071419565929100_bnag005-B57","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1101\/gad.276568.115","article-title":"Role of TET enzymes in DNA methylation, development, and cancer","volume":"30","author":"Rasmussen","year":"2016","journal-title":"Genes Dev"},{"issue":"3","key":"2026071419565929100_bnag005-B58","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrg3354","article-title":"DNA methylation: roles in mammalian development","volume":"14","author":"Smith","year":"2013","journal-title":"Nat Rev Genet"},{"issue":"3","key":"2026071419565929100_bnag005-B59","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res"},{"issue":"5","key":"2026071419565929100_bnag005-B60","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.cell.2009.06.049","article-title":"Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes","volume":"138","author":"Wang","year":"2009","journal-title":"Cell"},{"issue":"4","key":"2026071419565929100_bnag005-B61","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2007.05.009","article-title":"High-resolution profiling of histone methylations in the human genome","volume":"129","author":"Barski","year":"2007","journal-title":"Cell"},{"issue":"7280","key":"2026071419565929100_bnag005-B62","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature08911","article-title":"Chromatin remodelling during development","volume":"463","author":"Ho","year":"2010","journal-title":"Nature"},{"issue":"5","key":"2026071419565929100_bnag005-B63","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrg3413","article-title":"From neural development to cognition: unexpected roles for chromatin","volume":"14","author":"Ronan","year":"2013","journal-title":"Nat Rev Genet"},{"issue":"1","key":"2026071419565929100_bnag005-B64","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-biochem-051410-092902","article-title":"Genome regulation by long noncoding RNAs","volume":"81","author":"Rinn","year":"2012","journal-title":"Annu Rev Biochem"},{"issue":"3","key":"2026071419565929100_bnag005-B65","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0092-8674(92)90519-I","article-title":"The product of the mouse Xist gene is a 15 kb inactive X-specific transcript containing no conserved ORF and located in the nucleus","volume":"71","author":"Brockdorff","year":"1992","journal-title":"Cell"},{"issue":"7398","key":"2026071419565929100_bnag005-B66","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature11082","article-title":"Topological domains in mammalian genomes identified by analysis of chromatin interactions","volume":"485","author":"Dixon","year":"2012","journal-title":"Nature"},{"issue":"5","key":"2026071419565929100_bnag005-B67","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.cell.2015.04.004","article-title":"Disruptions of topological chromatin domains cause pathogenic rewiring of gene-enhancer interactions","volume":"161","author":"Lupi\u00e1\u00f1ez","year":"2015","journal-title":"Cell"},{"issue":"4","key":"2026071419565929100_bnag005-B68","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ajhg.2019.03.008","article-title":"Diagnostic utility of genome-wide DNA methylation testing in genetically unsolved individuals with suspected hereditary conditions","volume":"104","author":"Aref-Eshghi","year":"2019","journal-title":"Am J Hum Genet"},{"issue":"5","key":"2026071419565929100_bnag005-B69","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2217\/epi-2018-0192","article-title":"DNA methylation signatures in mendelian developmental disorders as a diagnostic bridge between genotype and phenotype","volume":"11","author":"Sadikovic","year":"2019","journal-title":"Epigenomics"},{"issue":"6","key":"2026071419565929100_bnag005-B70","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/s41436-020-01096-4","article-title":"Clinical epigenomics: genome-wide DNA methylation analysis for the diagnosis of Mendelian disorders","volume":"23","author":"Sadikovic","year":"2021","journal-title":"Genet Med"},{"issue":"11","key":"2026071419565929100_bnag005-B71","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/humu.24446","article-title":"Functional correlation of genome-wide DNA methylation profiles in genetic neurodevelopmental disorders","volume":"43","author":"Levy","year":"2022","journal-title":"Hum Mutat"},{"issue":"5","key":"2026071419565929100_bnag005-B72","doi-asserted-by":"crossref","first-page":"101075","DOI":"10.1016\/j.gim.2024.101075","article-title":"Diagnostic utility and reporting recommendations for clinical DNA methylation episignature testing in genetically undiagnosed rare diseases","volume":"26","author":"Kerkhof","year":"2024","journal-title":"Genet Med"},{"issue":"3","key":"2026071419565929100_bnag005-B73","first-page":"100309","article-title":"DNA methylation analysis in patients with neurodevelopmental disorders improves variant interpretation and reveals complexity","volume":"5","author":"Trajkova","year":"2024","journal-title":"HGG Adv"},{"issue":"3","key":"2026071419565929100_bnag005-B74","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/MED.0000000000000634","article-title":"Genetics of pheochromocytoma and paraganglioma","volume":"28","author":"Wachtel","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"2026071419565929100_bnag005-B75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ejendo\/lvae160","article-title":"Insights into the genetic landscape of pheochromocytomas and paragangliomas in a Brazilian cohort","volume":"192","author":"Fagundes","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2026071419565929100_bnag005-B76","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1210\/clinem\/dgaa502","article-title":"Sino-European differences in the genetic landscape and clinical presentation of pheochromocytoma and paraganglioma","volume":"105","author":"Jiang","year":"2020","journal-title":"J Clin Endocrinol Metabol"},{"issue":"1","key":"2026071419565929100_bnag005-B77","doi-asserted-by":"crossref","first-page":"101922","DOI":"10.1016\/j.beem.2024.101922","article-title":"Personalized management for phaeochromocytomas and paragangliomas in Latin America: a genetic perspective","volume":"39","author":"Freitas-Castro","year":"2025","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"8","key":"2026071419565929100_bnag005-B78","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1210\/clinem\/dgad028","article-title":"Evidence for a founder effect of SDHB exon 1 deletion in Brazilian patients with paraganglioma","volume":"108","author":"Fagundes","year":"2023","journal-title":"J Clin Endocrinol Metabol"},{"issue":"18","key":"2026071419565929100_bnag005-B79","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.3390\/cancers13184602","article-title":"Insights into mechanisms of pheochromocytomas and paragangliomas driven by known or new genetic drivers","volume":"13","author":"Flores","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2026071419565929100_bnag005-B80","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"issue":"9","key":"2026071419565929100_bnag005-B81","doi-asserted-by":"crossref","first-page":"e7094","DOI":"10.1371\/journal.pone.0007094","article-title":"The Warburg effect is genetically determined in inherited pheochromocytomas","volume":"4","author":"Favier","year":"2009","journal-title":"PLoS One"},{"issue":"12","key":"2026071419565929100_bnag005-B82","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1210\/me.2010-0256","article-title":"Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas","volume":"24","author":"L\u00f3pez-Jim\u00e9nez","year":"2010","journal-title":"Mol Endocrinol"},{"issue":"20","key":"2026071419565929100_bnag005-B83","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1093\/hmg\/ddr324","article-title":"Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma","volume":"20","author":"Burnichon","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2026071419565929100_bnag005-B84","doi-asserted-by":"crossref","first-page":"72\u2013","DOI":"10.1371\/journal.pgen.0010008","article-title":"A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas","volume":"1","author":"Dahia","year":"2005","journal-title":"PLoS Genet"},{"issue":"1","key":"2026071419565929100_bnag005-B85","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41467-023-36769-6","article-title":"Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma","volume":"14","author":"Calsina","year":"2023","journal-title":"Nat Commun"},{"issue":"10","key":"2026071419565929100_bnag005-B86","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3390\/cancers11101505","article-title":"Current management of pheochromocytoma\/paraganglioma: a guide for the practicing clinician in the era of precision medicine","volume":"11","author":"N\u00f6lting","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026071419565929100_bnag005-B87","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.surg.2016.05.050","article-title":"SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma","volume":"161","author":"Assadipour","year":"2017","journal-title":"Surgery"},{"issue":"3","key":"2026071419565929100_bnag005-B88","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41574-023-00926-0","article-title":"Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement","volume":"20","author":"Ta\u00efeb","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"2026071419565929100_bnag005-B89","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1158\/1078-0432.CCR-18-0139","article-title":"Telomerase activation and ATRX mutations are independent risk factors for metastatic pheochromocytoma and paraganglioma","volume":"25","author":"Job","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2026071419565929100_bnag005-B90","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ccr.2013.04.018","article-title":"SDH mutations establish a hypermethylator phenotype in paraganglioma","volume":"23","author":"Letouz\u00e9","year":"2013","journal-title":"Cancer Cell"},{"issue":"13","key":"2026071419565929100_bnag005-B91","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1158\/1078-0432.CCR-14-2804","article-title":"DNA methylation profiling in pheochromocytoma and paraganglioma reveals diagnostic and prognostic markers","volume":"21","author":"de Cubas","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026071419565929100_bnag005-B92","doi-asserted-by":"crossref","first-page":"44943","DOI":"10.1038\/srep44943","article-title":"Global DNA methylation analysis identifies two discrete clusters of pheochromocytoma with distinct genomic and genetic alterations","volume":"7","author":"Backman","year":"2017","journal-title":"Sci Rep"},{"issue":"8","key":"2026071419565929100_bnag005-B93","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1158\/0008-5472.CAN-17-2463","article-title":"Germline mutations in the mitochondrial 2-oxoglutarate\/malate carrier","volume":"78","author":"Buffet","year":"2018","journal-title":"Cancer Res"},{"issue":"1","key":"2026071419565929100_bnag005-B94","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","article-title":"Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase","volume":"7","author":"Selak","year":"2005","journal-title":"Cancer Cell"},{"issue":"12","key":"2026071419565929100_bnag005-B95","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1101\/gad.191056.112","article-title":"Inhibition of \u03b1-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors","volume":"26","author":"Xiao","year":"2012","journal-title":"Genes Dev"},{"issue":"1","key":"2026071419565929100_bnag005-B96","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/cge.13553","article-title":"Clinical implications of the oncometabolite succinate in SDHx-mutation carriers","volume":"97","author":"Eijkelenkamp","year":"2020","journal-title":"Clin Genet"},{"issue":"13","key":"2026071419565929100_bnag005-B97","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1016\/j.celrep.2020.03.022","article-title":"TET-mediated hypermethylation primes SDH-deficient cells for HIF2\u03b1-driven mesenchymal transition","volume":"30","author":"Morin","year":"2020","journal-title":"Cell Rep"},{"issue":"6","key":"2026071419565929100_bnag005-B98","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/2159-8290.CD-13-0092","article-title":"Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor","volume":"3","author":"Killian","year":"2013","journal-title":"Cancer Discov"},{"issue":"1","key":"2026071419565929100_bnag005-B99","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13148-023-01598-3","article-title":"A comprehensive characterisation of phaeochromocytoma and paraganglioma tumours through histone protein profiling, DNA methylation and transcriptomic analysis genome wide","volume":"15","author":"Chatzikyriakou","year":"2023","journal-title":"Clin Epigenet"},{"issue":"36","key":"2026071419565929100_bnag005-B100","doi-asserted-by":"crossref","first-page":"38777","DOI":"10.18632\/oncotarget.6091","article-title":"Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma\/pheochromocytoma and smooth muscle tumors","volume":"6","author":"Hoekstra","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"2026071419565929100_bnag005-B101","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/s41467-025-57595-y","article-title":"Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles","volume":"16","author":"Flynn","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"2026071419565929100_bnag005-B102","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1677\/ERC-10-0211","article-title":"Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma","volume":"18","author":"Eisenhofer","year":"2011","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2026071419565929100_bnag005-B103","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1530\/ERC-11-0243","article-title":"False-negative 123I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease","volume":"19","author":"Fonte","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2026071419565929100_bnag005-B104","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s12020-020-02594-w","article-title":"SDHB large deletions are associated with absence of MIBG uptake in metastatic lesions of malignant paragangliomas","volume":"72","author":"Petenuci","year":"2021","journal-title":"Endocrine"},{"issue":"6","key":"2026071419565929100_bnag005-B105","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1210\/jc.2009-2352","article-title":"6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression","volume":"95","author":"Fottner","year":"2010","journal-title":"J Clin Endocrinol Metabol"},{"issue":"32","key":"2026071419565929100_bnag005-B106","doi-asserted-by":"crossref","first-page":"32955","DOI":"10.18632\/oncotarget.5106","article-title":"Deciphering the molecular basis of invasiveness in Sdhb-deficient cells","volume":"6","author":"Loriot","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"2026071419565929100_bnag005-B107","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.4161\/cc.9.6.11006","article-title":"MicroRNA-210: a unique and pleiotropic hypoxamir","volume":"9","author":"Chan","year":"2010","journal-title":"Cell Cycle"},{"issue":"1","key":"2026071419565929100_bnag005-B108","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12020-021-02857-0","article-title":"A long noncoding RNA\u2013microRNA expression signature predicts metastatic signature in pheochromocytomas and paragangliomas","volume":"75","author":"Ghosal","year":"2022","journal-title":"Endocrine"},{"issue":"4","key":"2026071419565929100_bnag005-B109","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1530\/ERC-12-0183","article-title":"Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways","volume":"20","author":"De Cubas","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"2026071419565929100_bnag005-B110","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1002\/ijc.32654","article-title":"Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: a novel prognostic biomarker","volume":"146","author":"Ghosal","year":"2020","journal-title":"Int J Cancer"},{"issue":"9","key":"2026071419565929100_bnag005-B111","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/1078-0432.CCR-15-1841","article-title":"Recurrent mutations of chromatin-remodeling genes and kinase receptors in pheochromocytomas and paragangliomas","volume":"22","author":"Toledo","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2026071419565929100_bnag005-B112","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1476-4598-8-89","article-title":"Inhibition of succinate dehydrogenase dysregulates histone modification in mammalian cells","volume":"8","author":"Cervera","year":"2009","journal-title":"Mol Cancer"},{"issue":"11","key":"2026071419565929100_bnag005-B113","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1210\/jc.2006-0423","article-title":"High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing","volume":"91","author":"Brouwers","year":"2006","journal-title":"J Clin Endocrinol Metabol"},{"key":"2026071419565929100_bnag005-B114","first-page":"12","article-title":"DNA methylation analysis in malignant pheochromocytoma and paraganglioma","volume":"7","author":"Oishi","year":"2017","journal-title":"J Clin Transl Endocrinol"},{"issue":"11","key":"2026071419565929100_bnag005-B115","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1210\/jc.2018-01471","article-title":"Epigenetic deregulation of protocadherin PCDHGC3 in pheochromocytomas\/paragangliomas associated with SDHB mutations","volume":"104","author":"Bernardo-Casti\u00f1eira","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026071419565929100_bnag005-B116","doi-asserted-by":"crossref","first-page":"e230061","DOI":"10.1530\/ERC-23-0061","article-title":"Genetic variants and down-regulation of CACNA1H in pheochromocytoma","volume":"31","author":"Svahn","year":"2024","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"2026071419565929100_bnag005-B117","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1210\/clinem\/dgae797","article-title":"Biomarkers improving genetic and metastatic disease prediction in paraganglioma: insights from a prospective study","volume":"110","author":"Drossart","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026071419565929100_bnag005-B118","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1677\/ERC-07-0285","article-title":"Methylation of the p16INK4A promoter is associated with malignant behavior in abdominal extra-adrenal paragangliomas but not pheochromocytomas","volume":"15","author":"Kiss","year":"2008","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2026071419565929100_bnag005-B119","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1677\/ERC-10-0142","article-title":"MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets","volume":"17","author":"Meyer-Rochow","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2026071419565929100_bnag005-B120","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1530\/ERC-11-0308","article-title":"The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma","volume":"19","author":"Patterson","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"2026071419565929100_bnag005-B121","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1002\/ctm2.260","article-title":"Overexpression of miR-483-5p is confined to metastases and linked to high circulating levels in patients with metastatic pheochromocytoma\/paraganglioma","volume":"10","author":"Castro-Vega","year":"2020","journal-title":"Clin Transl Med"},{"issue":"17","key":"2026071419565929100_bnag005-B122","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.7150\/thno.35458","article-title":"Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p\/TSC2\/mTOR axis in metastatic pheochromocytoma\/paraganglioma","volume":"9","author":"Calsina","year":"2019","journal-title":"Theranostics"},{"issue":"1","key":"2026071419565929100_bnag005-B123","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.1038\/ncomms7044","article-title":"Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas","volume":"6","author":"Castro-Vega","year":"2015","journal-title":"Nat Commun"},{"key":"2026071419565929100_bnag005-B124","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.humpath.2017.03.017","article-title":"MicroRNA 183 family profiles in pheochromocytomas are related to clinical parameters and SDHB expression","volume":"64","author":"Pillai","year":"2017","journal-title":"Hum Pathol"},{"issue":"2","key":"2026071419565929100_bnag005-B125","first-page":"1545","article-title":"Role of miR-101 in pheochromocytoma patients with SDHD mutation","volume":"8","author":"Zong","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"issue":"6","key":"2026071419565929100_bnag005-B126","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1159\/000496043","article-title":"Building a competing endogenous RNA network to find potential long non-coding RNA biomarkers for pheochromocytoma","volume":"51","author":"Liang","year":"2018","journal-title":"Cell Physiol Biochem"},{"issue":"2","key":"2026071419565929100_bnag005-B127","doi-asserted-by":"crossref","first-page":"344","DOI":"10.21037\/tau.2020.01.29","article-title":"Integrative analysis of ceRNA network and DNA methylation associated with gene expression in malignant pheochromocytomas: a study based on The Cancer Genome Atlas","volume":"9","author":"Zhang","year":"2020","journal-title":"Transl Androl Urol"},{"issue":"3","key":"2026071419565929100_bnag005-B128","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1210\/clinem\/dgz168","article-title":"Transcriptome analysis of lncRNAs in pheochromocytomas and paragangliomas","volume":"105","author":"Job","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026071419565929100_bnag005-B129","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1677\/ERC-06-0031","article-title":"The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma","volume":"14","author":"Geli","year":"2007","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"2026071419565929100_bnag005-B130","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1158\/1078-0432.CCR-07-1867","article-title":"Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association to malignant behavior","volume":"14","author":"Geli","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"51","key":"2026071419565929100_bnag005-B131","doi-asserted-by":"crossref","first-page":"7573","DOI":"10.1038\/sj.onc.1204968","article-title":"RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours","volume":"20","author":"Astuti","year":"2001","journal-title":"Oncogene"},{"issue":"2","key":"2026071419565929100_bnag005-B132","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ccr.2005.06.015","article-title":"Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer","volume":"8","author":"Lee","year":"2005","journal-title":"Cancer Cell"},{"issue":"16","key":"2026071419565929100_bnag005-B133","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.1128\/MCB.02366-05","article-title":"Transcriptional pausing caused by NELF plays a dual role in regulating immediate-early expression of the junB gene","volume":"26","author":"Aida","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"25","key":"2026071419565929100_bnag005-B134","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1038\/onc.2011.475","article-title":"Junb promotes cell invasion and angiogenesis in VHL-defective renal cell carcinoma","volume":"31","author":"Kanno","year":"2012","journal-title":"Oncogene"},{"issue":"2","key":"2026071419565929100_bnag005-B135","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s40200-024-01466-8","article-title":"The role of methylation quantification of circulating tumor DNA (ctDNA) as a diagnostic biomarker of Pheochromocytomas (PCCs) and Paragangliomas (PGLs)","volume":"23","author":"Khatami","year":"2024","journal-title":"J Diabetes Metab Disord"},{"issue":"47","key":"2026071419565929100_bnag005-B136","doi-asserted-by":"crossref","first-page":"47070","DOI":"10.1074\/jbc.M310075200","article-title":"The acyl-CoA synthetase \u201cbubblegum\u201d (lipidosin): further characterization and role in neuronal fatty acid beta-oxidation","volume":"278","author":"Pei","year":"2003","journal-title":"J Biol Chem"},{"issue":"2","key":"2026071419565929100_bnag005-B137","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10549-009-0404-3","article-title":"Association of genetic variation in mitotic kinases with breast cancer risk","volume":"119","author":"Wang","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"2026071419565929100_bnag005-B138","doi-asserted-by":"crossref","first-page":"6689","DOI":"10.1074\/jbc.M008127200","article-title":"An ephrin-A-dependent signaling pathway controls integrin function and is linked to the tyrosine phosphorylation of a 120-kDa protein","volume":"276","author":"Huai","year":"2001","journal-title":"J Biol Chem"},{"issue":"4","key":"2026071419565929100_bnag005-B139","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1089\/dna.2019.5167","article-title":"The role of high-risk human papillomavirus-related long non-coding RNAs in the prognosis of cervical squamous cell carcinoma","volume":"39","author":"Cheng","year":"2020","journal-title":"DNA Cell Biol"},{"issue":"1","key":"2026071419565929100_bnag005-B140","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12935-020-01205-y","article-title":"Long noncoding RNA BSN-AS2 induced by E2F1 promotes spinal osteosarcoma progression by targeting miR-654-3p\/SYTL2 axis","volume":"20","author":"Zhou","year":"2020","journal-title":"Cancer Cell Int"},{"key":"2026071419565929100_bnag005-B141","doi-asserted-by":"crossref","first-page":"151801","DOI":"10.1016\/j.anndiagpath.2021.151801","article-title":"LncRNA expression and SDHB mutations in pheochromocytomas and paragangliomas","volume":"55","author":"Li","year":"2021","journal-title":"Ann Diagn Pathol"},{"issue":"19","key":"2026071419565929100_bnag005-B142","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1002\/cncr.35426","article-title":"Role of epigenetic regulation on catecholamine synthesis in pheochromocytoma and paraganglioma","volume":"130","author":"Kaplinsky","year":"2024","journal-title":"Cancer"},{"issue":"12","key":"2026071419565929100_bnag005-B143","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/modpathol.2010.164","article-title":"MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas","volume":"23","author":"T\u00f6mb\u00f6l","year":"2010","journal-title":"Mod Pathol"},{"issue":"1","key":"2026071419565929100_bnag005-B144","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13148-022-01347-y","article-title":"Whole blood methylome-derived features to discriminate endocrine hypertension","volume":"14","author":"Armignacco","year":"2022","journal-title":"Clin Epigenet"},{"issue":"7643","key":"2026071419565929100_bnag005-B145","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature21063","article-title":"Whole-genome landscape of pancreatic neuroendocrine tumours","volume":"543","author":"Scarpa","year":"2017","journal-title":"Nature"},{"issue":"1","key":"2026071419565929100_bnag005-B146","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41416-024-02705-8","article-title":"Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms","volume":"131","author":"Angerilli","year":"2024","journal-title":"Br J Cancer"},{"issue":"2","key":"2026071419565929100_bnag005-B147","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1210\/endrev\/bnaa031","article-title":"Multiple endocrine neoplasia type 1: latest insights","volume":"42","author":"Brandi","year":"2021","journal-title":"Endocr Rev"},{"issue":"8","key":"2026071419565929100_bnag005-B148","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/cncr.31930","article-title":"Distinct genome-wide methylation patterns in sporadic and hereditary nonfunctioning pancreatic neuroendocrine tumors","volume":"125","author":"Tirosh","year":"2019","journal-title":"Cancer"},{"issue":"32","key":"2026071419565929100_bnag005-B149","doi-asserted-by":"crossref","first-page":"14075","DOI":"10.1073\/pnas.1008850107","article-title":"Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres","volume":"107","author":"Lewis","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2026071419565929100_bnag005-B150","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1053\/j.gastro.2013.10.020","article-title":"Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors","volume":"146","author":"Marinoni","year":"2014","journal-title":"Gastroenterology"},{"issue":"3","key":"2026071419565929100_bnag005-B151","doi-asserted-by":"crossref","first-page":"L13","DOI":"10.1530\/ERC-15-0108","article-title":"Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours","volume":"22","author":"Pipinikas","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2026071419565929100_bnag005-B152","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/gutjnl-2020-322595","article-title":"Non-functional pancreatic neuroendocrine tumours: ATRX\/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX\/PDX1 expression and tumour size","volume":"71","author":"Hackeng","year":"2022","journal-title":"Gut"},{"issue":"6","key":"2026071419565929100_bnag005-B153","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1172\/JCI67963","article-title":"The genomic landscape of small intestine neuroendocrine tumors","volume":"123","author":"Banck","year":"2013","journal-title":"J Clin Invest"},{"issue":"6021","key":"2026071419565929100_bnag005-B154","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"issue":"22","key":"2026071419565929100_bnag005-B155","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1158\/1078-0432.CCR-20-1804","article-title":"Comprehensive genomic profiling of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)","volume":"26","author":"Puccini","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2026071419565929100_bnag005-B156","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ccell.2015.12.012","article-title":"Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma","volume":"29","author":"Yachida","year":"2016","journal-title":"Cancer Cell"},{"issue":"9","key":"2026071419565929100_bnag005-B157","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"issue":"3","key":"2026071419565929100_bnag005-B158","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1158\/2159-8290.CD-21-0669","article-title":"Comprehensive genomic profiling of neuroendocrine carcinomas of the gastrointestinal system","volume":"12","author":"Yachida","year":"2022","journal-title":"Cancer Discov"},{"issue":"2","key":"2026071419565929100_bnag005-B159","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/PAS.0b013e3182417d36","article-title":"Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors","volume":"36","author":"Yachida","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2026071419565929100_bnag005-B160","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1038\/s41467-021-24812-3","article-title":"The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets","volume":"12","author":"van Riet","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"2026071419565929100_bnag005-B161","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-21-0152","article-title":"The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"29","author":"Venizelos","year":"2022","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2026071419565929100_bnag005-B162","doi-asserted-by":"crossref","first-page":"100065","DOI":"10.1016\/j.modpat.2022.100065","article-title":"Integrated genomic and clinicopathologic approach distinguishes pancreatic grade 3 neuroendocrine tumor from neuroendocrine carcinoma and identifies a subset with molecular overlap","volume":"36","author":"Umetsu","year":"2023","journal-title":"Mod Pathol"},{"issue":"8","key":"2026071419565929100_bnag005-B163","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.humpath.2010.01.011","article-title":"DNA methyltransferases 1, 3a, and 3b overexpression and clinical significance in gastroenteropancreatic neuroendocrine tumors","volume":"41","author":"Rahman","year":"2010","journal-title":"Hum Pathol"},{"issue":"3","key":"2026071419565929100_bnag005-B164","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/01.sla.0000086659.49569.9e","article-title":"Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms","volume":"238","author":"House","year":"2003","journal-title":"Ann Surg"},{"issue":"24","key":"2026071419565929100_bnag005-B165","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1038\/sj.onc.1206582","article-title":"Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma","volume":"22","author":"Dammann","year":"2003","journal-title":"Oncogene"},{"issue":"1","key":"2026071419565929100_bnag005-B166","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/1471-2407-11-351","article-title":"Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors","volume":"11","author":"Malpeli","year":"2011","journal-title":"BMC Cancer"},{"issue":"3","key":"2026071419565929100_bnag005-B167","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1530\/EJE-18-0195","article-title":"DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment","volume":"179","author":"Conemans","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2026071419565929100_bnag005-B168","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1002\/ijc.22569","article-title":"Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system","volume":"120","author":"Arnold","year":"2007","journal-title":"Int J Cancer"},{"issue":"3","key":"2026071419565929100_bnag005-B169","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s12020-006-0008-1","article-title":"Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors","volume":"30","author":"Zhang","year":"2006","journal-title":"Endocrine"},{"issue":"12","key":"2026071419565929100_bnag005-B170","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/modpathol.3800490","article-title":"Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis","volume":"18","author":"Liu","year":"2005","journal-title":"Mod Pathol"},{"issue":"2","key":"2026071419565929100_bnag005-B171","first-page":"237","article-title":"Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16\/MTS1 tumor suppressor gene inactivation","volume":"58","author":"Muscarella","year":"1998","journal-title":"Cancer Res"},{"issue":"11","key":"2026071419565929100_bnag005-B172","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/jcem.85.11.6970","article-title":"Alterations in the p16INK4a\/CDKN2A tumor suppressor gene in gastrinomas","volume":"85","author":"Serrano","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"2-3","key":"2026071419565929100_bnag005-B173","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000007810","article-title":"Low frequency of p16INK4a alterations in insulinomas","volume":"62","author":"Bartsch","year":"2000","journal-title":"Digestion"},{"issue":"6","key":"2026071419565929100_bnag005-B174","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.onc.1206123","article-title":"Cpg island methylation in carcinoid and pancreatic endocrine tumors","volume":"22","author":"Chan","year":"2003","journal-title":"Oncogene"},{"issue":"23","key":"2026071419565929100_bnag005-B175","doi-asserted-by":"crossref","first-page":"E2404","DOI":"10.1073\/pnas.1319962111","article-title":"PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors","volume":"111","author":"Ohki","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2026071419565929100_bnag005-B176","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/modpathol.3800825","article-title":"Hypomethylation of LINE-1 and alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors)","volume":"20","author":"Choi","year":"2007","journal-title":"Mod Pathol"},{"issue":"1","key":"2026071419565929100_bnag005-B177","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000365449","article-title":"Prognostic relevance of aberrant DNA methylation in g1 and g2 pancreatic neuroendocrine tumors","volume":"100","author":"Stefanoli","year":"2014","journal-title":"Neuroendocrinology"},{"issue":"3","key":"2026071419565929100_bnag005-B178","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1210\/jc.2002-021027","article-title":"Frequent methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene in pancreatic endocrine tumors","volume":"88","author":"Wild","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071419565929100_bnag005-B179","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejca.2022.09.009","article-title":"Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy","volume":"176","author":"Evans","year":"2022","journal-title":"Eur J Cancer"},{"issue":"4-5","key":"2026071419565929100_bnag005-B180","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/path.6291","article-title":"PCDHGC3 hypermethylation as a potential biomarker of intestinal neuroendocrine carcinomas","volume":"263","author":"Cubiella","year":"2024","journal-title":"J Pathol"},{"issue":"9","key":"2026071419565929100_bnag005-B181","first-page":"3699","article-title":"Site- and grade-specific diversity of LINE1 methylation pattern in gastroenteropancreatic neuroendocrine tumours","volume":"32","author":"Stricker","year":"2012","journal-title":"Anticancer Res"},{"issue":"1","key":"2026071419565929100_bnag005-B182","first-page":"e230003","article-title":"The role of DNA methylation in human pancreatic neuroendocrine tumours","volume":"3","author":"English","year":"2023","journal-title":"Endocr Oncol"},{"issue":"50","key":"2026071419565929100_bnag005-B183","doi-asserted-by":"crossref","first-page":"e2224","DOI":"10.1097\/MD.0000000000002224","article-title":"High expression of microRNA-196a indicates poor prognosis in resected pancreatic neuroendocrine tumor","volume":"94","author":"Lee","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2026071419565929100_bnag005-B184","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1530\/EJE-18-0305","article-title":"Prognostic relevance of proliferation-related miRNAs in pancreatic neuroendocrine neoplasms","volume":"179","author":"Grolmusz","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"2026071419565929100_bnag005-B185","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3389\/fonc.2020.01187","article-title":"Altered miRNAs expression correlates with gastroenteropancreatic neuroendocrine tumors grades","volume":"10","author":"Cavalcanti","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"2026071419565929100_bnag005-B186","doi-asserted-by":"crossref","first-page":"368504251326864","DOI":"10.1177\/00368504251326864","article-title":"miRNA profile in pancreatic neuroendocrine tumors: preliminary results","volume":"108","author":"Ciobanu","year":"2025","journal-title":"Sci Prog"},{"issue":"14","key":"2026071419565929100_bnag005-B187","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.3390\/cancers16142528","article-title":"miRNA expression profiling in G1 and G2 pancreatic neuroendocrine tumors","volume":"16","author":"Nyir\u0151","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2026071419565929100_bnag005-B188","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2217\/epi.15.85","article-title":"DNA methylation profiles distinguish different subtypes of gastroenteropancreatic neuroendocrine tumors","volume":"7","author":"How-Kit","year":"2015","journal-title":"Epigenomics"},{"issue":"5","key":"2026071419565929100_bnag005-B189","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1158\/1078-0432.CCR-20-3281","article-title":"Genome methylation accurately predicts neuroendocrine tumor origin: an online tool","volume":"27","author":"Hackeng","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2026071419565929100_bnag005-B190","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1677\/ERC-08-0331","article-title":"Hypermethylation of the IGF2 differentially methylated region 2 is a specific event in insulinomas leading to loss-of-imprinting and overexpression","volume":"16","author":"Dejeux","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2026071419565929100_bnag005-B191","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s42003-020-01479-y","article-title":"Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression","volume":"3","author":"Di Domenico","year":"2020","journal-title":"Commun Biol"},{"issue":"1","key":"2026071419565929100_bnag005-B192","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s42003-020-01469-0","article-title":"DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association","volume":"4","author":"Lakis","year":"2021","journal-title":"Commun Biol"},{"issue":"1","key":"2026071419565929100_bnag005-B193","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13073-022-01018-w","article-title":"DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors","volume":"14","author":"Simon","year":"2022","journal-title":"Genome Med"},{"issue":"1","key":"2026071419565929100_bnag005-B194","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1038\/s41467-018-06498-2","article-title":"ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup","volume":"9","author":"Chan","year":"2018","journal-title":"Nat Commun"},{"issue":"2","key":"2026071419565929100_bnag005-B195","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1097\/PAI.0000000000000982","article-title":"Epigenetic dysregulation of 5-hydroxymethylcytosine in well-differentiated pancreatic neuroendocrine tumors","volume":"30","author":"Sharma","year":"2022","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"2","key":"2026071419565929100_bnag005-B196","doi-asserted-by":"crossref","first-page":"L21","DOI":"10.1530\/ERC-16-0419","article-title":"Progressive epigenetic dysregulation in neuroendocrine tumour liver metastases","volume":"24","author":"Karpathakis","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2026071419565929100_bnag005-B197","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1158\/1078-0432.CCR-15-0373","article-title":"Prognostic impact of novel molecular subtypes of small intestinal neuroendocrine tumor","volume":"22","author":"Karpathakis","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2026071419565929100_bnag005-B198","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s12020-017-1474-3","article-title":"Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study","volume":"60","author":"Campana","year":"2018","journal-title":"Endocrine"},{"issue":"8","key":"2026071419565929100_bnag005-B199","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1530\/ERC-16-0117","article-title":"MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors","volume":"23","author":"Cros","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"29","key":"2026071419565929100_bnag005-B200","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1200\/JCO.2005.05.5194","article-title":"MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior","volume":"24","author":"Roldo","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026071419565929100_bnag005-B201","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1530\/ERC-22-0045","article-title":"miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2","volume":"29","author":"Kooblall","year":"2022","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2026071419565929100_bnag005-B202","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000487326","article-title":"A comprehensive assessment of the role of miRNAs as biomarkers in gastroenteropancreatic neuroendocrine tumors","volume":"107","author":"Malczewska","year":"2018","journal-title":"Neuroendocrinology"},{"issue":"5","key":"2026071419565929100_bnag005-B203","first-page":"2249","article-title":"Global microRNA profiling of pancreatic neuroendocrine neoplasias","volume":"34","author":"Thorns","year":"2014","journal-title":"Anticancer Res"},{"issue":"9","key":"2026071419565929100_bnag005-B204","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1245\/s10434-020-08377-x","article-title":"Accuracy of grading in pancreatic neuroendocrine neoplasms and effect on survival estimates: an institutional experience","volume":"27","author":"Trikalinos","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"47","key":"2026071419565929100_bnag005-B205","doi-asserted-by":"crossref","first-page":"28379","DOI":"10.18632\/oncotarget.25357","article-title":"MicroRNA analysis of gastroenteropancreatic neuroendocrine tumors and metastases","volume":"9","author":"Zimmermann","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"2026071419565929100_bnag005-B206","doi-asserted-by":"crossref","first-page":"e0125553","DOI":"10.1371\/journal.pone.0125553","article-title":"Somatostatin analogs treated small intestinal neuroendocrine tumor patients circulating microRNAs","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"2026071419565929100_bnag005-B207","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12967-022-03511-7","article-title":"Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis","volume":"20","author":"Melone","year":"2022","journal-title":"J Transl Med"},{"issue":"3","key":"2026071419565929100_bnag005-B208","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1073\/pnas.0408836102","article-title":"Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors","volume":"102","author":"Milne","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2026071419565929100_bnag005-B209","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1530\/ERC-17-0328","article-title":"Tumor suppressor functions of DAXX through histone H3.3\/H3K9me3 pathway in pancreatic NETs","volume":"25","author":"Ueda","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"7563","key":"2026071419565929100_bnag005-B210","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"issue":"10","key":"2026071419565929100_bnag005-B211","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.2396","article-title":"Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer","volume":"44","author":"Peifer","year":"2012","journal-title":"Nat Genet"},{"issue":"48","key":"2026071419565929100_bnag005-B212","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1038\/onc.2015.38","article-title":"DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2","volume":"34","author":"Poirier","year":"2015","journal-title":"Oncogene"},{"issue":"14","key":"2026071419565929100_bnag005-B213","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1158\/1078-0432.CCR-15-2946","article-title":"Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets","volume":"22","author":"Rekhtman","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2026071419565929100_bnag005-B214","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/path.4853","article-title":"Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D","volume":"241","author":"Simbolo","year":"2017","journal-title":"J Pathol"},{"issue":"1","key":"2026071419565929100_bnag005-B215","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1038\/ncomms4518","article-title":"Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids","volume":"5","author":"Fernandez-Cuesta","year":"2014","journal-title":"Nat Commun"},{"issue":"23","key":"2026071419565929100_bnag005-B216","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1158\/1078-0432.CCR-14-1087","article-title":"Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome","volume":"20","author":"Karlsson","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2026071419565929100_bnag005-B217","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.3390\/cancers12082003","article-title":"Methylation patterns and chromatin accessibility in neuroendocrine lung cancer","volume":"12","author":"Arbajian","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"12","key":"2026071419565929100_bnag005-B218","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/ijc.33939","article-title":"Differential Orthopedia Homeobox expression in pulmonary carcinoids is associated with changes in DNA methylation","volume":"150","author":"Moonen","year":"2022","journal-title":"Int J Cancer"},{"issue":"9","key":"2026071419565929100_bnag005-B219","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.3390\/cancers12092653","article-title":"Classifying lung neuroendocrine neoplasms through microRNA sequence data mining","volume":"12","author":"Wong","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2026071419565929100_bnag005-B220","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.1440-1827.2012.02845.x","article-title":"Altered expression of microRNA miR-21, miR-155, and let-7a and their roles in pulmonary neuroendocrine tumors","volume":"62","author":"Lee","year":"2012","journal-title":"Pathol Int"},{"issue":"12","key":"2026071419565929100_bnag005-B221","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/modpathol.2014.74","article-title":"Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumors of the lung: results of a profiling study","volume":"27","author":"Mairinger","year":"2014","journal-title":"Mod Pathol"},{"issue":"8","key":"2026071419565929100_bnag005-B222","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1097\/JTO.0b013e3181dea6be","article-title":"MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer","volume":"5","author":"Ranade","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"5","key":"2026071419565929100_bnag005-B223","doi-asserted-by":"crossref","first-page":"8723","DOI":"10.1002\/jcb.28159","article-title":"A three microRNA-based prognostic signature for small cell lung cancer overall survival","volume":"120","author":"Yan","year":"2019","journal-title":"J Cell Biochem"},{"issue":"5","key":"2026071419565929100_bnag005-B224","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/PAI.0b013e3182108e2e","article-title":"Epigenetic modifications of histone h4 in lung neuroendocrine tumors","volume":"19","author":"Li","year":"2011","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"27","key":"2026071419565929100_bnag005-B225","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1038\/sj.onc.1204469","article-title":"The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas","volume":"20","author":"Dammann","year":"2001","journal-title":"Oncogene"},{"issue":"3","key":"2026071419565929100_bnag005-B226","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/sj.cdd.4401157","article-title":"Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation","volume":"10","author":"Hopkins-Donaldson","year":"2003","journal-title":"Cell Death Differ"},{"issue":"30","key":"2026071419565929100_bnag005-B227","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1038\/onc.2012.362","article-title":"The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells","volume":"32","author":"Kalari","year":"2013","journal-title":"Oncogene"},{"key":"2026071419565929100_bnag005-B228","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.semcancer.2020.11.006","article-title":"Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease","volume":"83","author":"Khan","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"2026071419565929100_bnag005-B229","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccell.2024.01.001","article-title":"Tumor-and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes","volume":"42","author":"Heeke","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"2026071419565929100_bnag005-B230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-020-00876-8","article-title":"Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets","volume":"12","author":"Krushkal","year":"2020","journal-title":"Clin Epigenet"},{"issue":"1","key":"2026071419565929100_bnag005-B231","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12022-025-09847-2","article-title":"Methylation profiles differ according to clinical characteristics in well-differentiated neuroendocrine tumors of the lung","volume":"36","author":"Melhorn","year":"2025","journal-title":"Endocr Pathol"},{"issue":"1","key":"2026071419565929100_bnag005-B232","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-021-01024-6","article-title":"DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancer","volume":"13","author":"Goldmann","year":"2021","journal-title":"Clin Epigenet"},{"issue":"6","key":"2026071419565929100_bnag005-B233","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/JTO.0b013e3181d6e0b3","article-title":"Methylation markers for small cell lung cancer in peripheral blood leukocyte DNA","volume":"5","author":"Wang","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2026071419565929100_bnag005-B234","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s12022-020-09626-1","article-title":"Long non-coding RNAs in pulmonary neuroendocrine neoplasms","volume":"31","author":"Narayanan","year":"2020","journal-title":"Endocr Pathol"},{"issue":"5","key":"2026071419565929100_bnag005-B235","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ccell.2025.03.027","article-title":"Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation","volume":"43","author":"Teng","year":"2025","journal-title":"Cancer Cell"},{"key":"2026071419565929100_bnag005-B236","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.csbj.2018.06.001","article-title":"Lung cancer therapy targeting histone methylation: opportunities and challenges","volume":"16","author":"Chen","year":"2018","journal-title":"Comput Struct Biotechnol J"},{"issue":"4","key":"2026071419565929100_bnag005-B237","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.molmed.2019.02.009","article-title":"Taking SCLC on a bad LSD (1) trip one NOTCH further","volume":"25","author":"Kim","year":"2019","journal-title":"Trends Mol Med"},{"issue":"6","key":"2026071419565929100_bnag005-B238","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1101\/gad.563210","article-title":"Histone demethylase KDM5A is an integral part of the core Notch\u2013RBP-J repressor complex","volume":"24","author":"Liefke","year":"2010","journal-title":"Genes Dev"},{"issue":"23-24","key":"2026071419565929100_bnag005-B239","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1101\/gad.328336.119","article-title":"The KDM5A\/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis","volume":"33","author":"Oser","year":"2019","journal-title":"Genes Dev"},{"issue":"4","key":"2026071419565929100_bnag005-B240","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jtho.2016.12.011","article-title":"Small cell lung cancer exhibits frequent inactivating mutations in the histone methyltransferase KMT2D\/MLL2: CALGB 151111 (alliance)","volume":"12","author":"Augert","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"12","key":"2026071419565929100_bnag005-B241","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1164\/rccm.202110-2358OC","article-title":"Transcriptional circuitry of NKX2-1 and SOX1 defines an unrecognized lineage subtype of small-cell lung cancer","volume":"206","author":"Kong","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2026071419565929100_bnag005-B242","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1038\/s41467-019-11276-9","article-title":"Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids","volume":"10","author":"Alcala","year":"2019","journal-title":"Nat Commun"},{"issue":"6","key":"2026071419565929100_bnag005-B243","doi-asserted-by":"crossref","first-page":"e21300","DOI":"10.1371\/journal.pone.0021300","article-title":"MicroRNA expression and clinical outcome of small cell lung cancer","volume":"6","author":"Lee","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"2026071419565929100_bnag005-B244","doi-asserted-by":"crossref","first-page":"10455","DOI":"10.1038\/s41598-021-89855-4","article-title":"A miR-375\/YAP axis regulates neuroendocrine differentiation and tumorigenesis in lung carcinoid cells","volume":"11","author":"Yang","year":"2021","journal-title":"Sci Rep"},{"issue":"567","key":"2026071419565929100_bnag005-B245","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aau2922","article-title":"Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition","volume":"12","author":"Augert","year":"2019","journal-title":"Sci Signal"},{"issue":"38","key":"2026071419565929100_bnag005-B246","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1038\/s41388-024-03125-x","article-title":"Jumonji histone demethylases are therapeutic targets in small cell lung cancer","volume":"43","author":"Nguyen","year":"2024","journal-title":"Oncogene"},{"issue":"1","key":"2026071419565929100_bnag005-B247","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"issue":"2","key":"2026071419565929100_bnag005-B248","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","article-title":"Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis","volume":"31","author":"Gardner","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"2026071419565929100_bnag005-B249","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/celldisc.2015.26","article-title":"EZH2 promotes progression of small cell lung cancer by suppressing the TGF-\u03b2-smad-ASCL1 pathway","volume":"1","author":"Murai","year":"2015","journal-title":"Cell Discov"},{"issue":"4","key":"2026071419565929100_bnag005-B250","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1586\/14737140.8.4.625","article-title":"RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer","volume":"8","author":"Lodish","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"issue":"13","key":"2026071419565929100_bnag005-B251","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1158\/1078-0432.CCR-11-2700","article-title":"Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases","volume":"18","author":"Tamburrino","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2026071419565929100_bnag005-B252","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1530\/EJE-14-0389","article-title":"mTOR activation in medullary thyroid carcinoma with RAS mutation","volume":"171","author":"Lyra","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2026071419565929100_bnag005-B253","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/hmg\/2.7.851","article-title":"Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC","volume":"2","author":"Donis-Keller","year":"1993","journal-title":"Hum Mol Genet"},{"issue":"6461","key":"2026071419565929100_bnag005-B254","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/367375a0","article-title":"A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma","volume":"367","author":"Hofstra","year":"1994","journal-title":"Nature"},{"issue":"9","key":"2026071419565929100_bnag005-B255","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/GIM.0b013e318216cc6d","article-title":"Multiple endocrine neoplasia type 2: an overview","volume":"13","author":"Moline","year":"2011","journal-title":"Genet Med"},{"issue":"5","key":"2026071419565929100_bnag005-B256","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","article-title":"The importance of the RET gene in thyroid cancer and therapeutic implications","volume":"17","author":"Salvatore","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"2026071419565929100_bnag005-B257","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"issue":"1","key":"2026071419565929100_bnag005-B258","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"3","key":"2026071419565929100_bnag005-B259","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/humu.23378","article-title":"Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer","volume":"39","author":"Sponziello","year":"2018","journal-title":"Hum Mutat"},{"issue":"9","key":"2026071419565929100_bnag005-B260","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1093\/hmg\/ddw057","article-title":"Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression","volume":"25","author":"Smith","year":"2016","journal-title":"Hum Mol Genet"},{"key":"2026071419565929100_bnag005-B261","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","article-title":"Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing","volume":"20","author":"Ciampi","year":"2019","journal-title":"iScience"},{"issue":"7","key":"2026071419565929100_bnag005-B262","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1089\/thy.2019.0531","article-title":"Genomic and transcriptomic characterization of sporadic medullary thyroid carcinoma","volume":"30","author":"Qu","year":"2020","journal-title":"Thyroid"},{"issue":"3","key":"2026071419565929100_bnag005-B263","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1210\/jc.2007-1714","article-title":"Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study","volume":"93","author":"Elisei","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026071419565929100_bnag005-B264","doi-asserted-by":"crossref","first-page":"E863","DOI":"10.1210\/jc.2010-1921","article-title":"High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas","volume":"96","author":"Moura","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026071419565929100_bnag005-B265","doi-asserted-by":"crossref","first-page":"E2031-","DOI":"10.1210\/jc.2012-2092","article-title":"Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon","volume":"97","author":"Boichard","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026071419565929100_bnag005-B266","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1089\/thy.2012.0207","article-title":"Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series","volume":"23","author":"Ciampi","year":"2013","journal-title":"Thyroid"},{"issue":"6","key":"2026071419565929100_bnag005-B267","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae059","article-title":"Not only RET but NF1 and chromosomal instability are seen in young patients with sporadic medullary thyroid carcinoma","volume":"8","author":"Castroneves","year":"2024","journal-title":"J Endocr Soc"},{"issue":"11","key":"2026071419565929100_bnag005-B268","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1089\/thy.2016.0224","article-title":"Role of CDKN2C copy number in sporadic medullary thyroid carcinoma","volume":"26","author":"Grubbs","year":"2016","journal-title":"Thyroid"},{"issue":"5","key":"2026071419565929100_bnag005-B269","first-page":"523","article-title":"Role of CDKN2C fluorescence in situ hybridization in the management of medullary thyroid carcinoma","volume":"47","author":"Naofal M","year":"2017","journal-title":"Ann Clin Lab Sci"},{"issue":"4","key":"2026071419565929100_bnag005-B270","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1210\/jc.2002-021155","article-title":"Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma","volume":"88","author":"Marsh","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026071419565929100_bnag005-B271","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1172\/JCI115186","article-title":"Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas","volume":"87","author":"Khosla","year":"1991","journal-title":"J Clin Invest"},{"issue":"2","key":"2026071419565929100_bnag005-B272","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1002\/ijc.26494","article-title":"High-resolution analysis of alterations in medullary thyroid carcinoma genomes","volume":"131","author":"Flicker","year":"2012","journal-title":"Int J Cancer"},{"issue":"8","key":"2026071419565929100_bnag005-B273","doi-asserted-by":"crossref","first-page":"e1005467","DOI":"10.1371\/journal.pgen.1005467","article-title":"Identification of driving ALK fusion genes and genomic landscape of medullary thyroid cancer","volume":"11","author":"Ji","year":"2015","journal-title":"PLoS Genet"},{"issue":"16","key":"2026071419565929100_bnag005-B274","doi-asserted-by":"crossref","first-page":"21332","DOI":"10.18632\/oncotarget.7237","article-title":"Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"2026071419565929100_bnag005-B275","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1158\/1078-0432.CCR-23-2142","article-title":"Comprehensive DNA methylation profiling of medullary thyroid carcinoma: molecular classification, potential therapeutic target, and classifier system","volume":"30","author":"Shen","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1-2","key":"2026071419565929100_bnag005-B276","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.mce.2014.04.016","article-title":"Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours","volume":"392","author":"Sponziello","year":"2014","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"2026071419565929100_bnag005-B277","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3390\/cancers17050737","article-title":"Validation of the international medullary thyroid cancer grading system and identification of EZH2 as a prognostic and potential therapeutic marker in medullary thyroid cancer","volume":"17","author":"Jager","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2026071419565929100_bnag005-B278","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1089\/thy.2012.0045","article-title":"MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome","volume":"22","author":"Mian","year":"2012","journal-title":"Thyroid"},{"key":"2026071419565929100_bnag005-B279","doi-asserted-by":"crossref","first-page":"4915736","DOI":"10.1155\/2017\/4915736","article-title":"Prognostic impact of miR-224 and RAS mutations in medullary thyroid carcinoma","volume":"2017","author":"Cavedon","year":"2017","journal-title":"Int J Endocrinol"},{"issue":"1","key":"2026071419565929100_bnag005-B280","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.humpath.2014.09.006","article-title":"The PDCD4\/miR-21 pathway in medullary thyroid carcinoma","volume":"46","author":"Pennelli","year":"2015","journal-title":"Hum Pathol"},{"issue":"14","key":"2026071419565929100_bnag005-B281","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1158\/1078-0432.CCR-11-0242","article-title":"MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets","volume":"17","author":"Abraham","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2026071419565929100_bnag005-B282","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1445-2197.2012.06291.x","article-title":"Nodal metastasis microRNA expression correlates with the primary tumour in MTC","volume":"84","author":"Gundara","year":"2014","journal-title":"ANZ J Surg"},{"issue":"4","key":"2026071419565929100_bnag005-B283","first-page":"3316","article-title":"Mir-592 acts as an oncogene and promotes medullary thyroid cancer tumorigenesis by targeting cyclin-dependent kinase 8","volume":"22","author":"Liu","year":"2020","journal-title":"Mol Med Rep"},{"issue":"6","key":"2026071419565929100_bnag005-B284","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1530\/ERC-13-0357","article-title":"A miRNA signature associated with human metastatic medullary thyroid carcinoma","volume":"20","author":"Santarpia","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2026071419565929100_bnag005-B285","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/ERC-17-0389","article-title":"Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients","volume":"25","author":"Romeo","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2026071419565929100_bnag005-B286","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00428-017-2227-7","article-title":"MiR-375 and YAP1 expression profiling in medullary thyroid carcinoma and their correlation with clinical-pathological features and outcome","volume":"471","author":"Galuppini","year":"2017","journal-title":"Virchows Arch"},{"key":"2026071419565929100_bnag005-B287","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.12659\/MSM.916815","article-title":"Two GEO MicroRNA expression profile based high-throughput screen to identify microRNA-31-3p regulating growth of medullary thyroid carcinoma cell by targeting RASA2","volume":"25","author":"Jiang","year":"2019","journal-title":"Med Sci Monit"},{"issue":"1","key":"2026071419565929100_bnag005-B288","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13046-021-01964-0","article-title":"circPVT1 regulates medullary thyroid cancer growth and metastasis by targeting miR-455-5p to activate CXCL12\/CXCR4 signaling","volume":"40","author":"Zheng","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2026071419565929100_bnag005-B289","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.yexmp.2018.06.003","article-title":"Global DNA methylation profile in medullary thyroid cancer patients","volume":"105","author":"Ceolin","year":"2018","journal-title":"Exp Mol Pathol"},{"issue":"7","key":"2026071419565929100_bnag005-B290","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1210\/jc.2012-3566","article-title":"DNA methylation signatures identify biologically distinct thyroid cancer subtypes","volume":"98","author":"Rodr\u00edguez-Rodero","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"13","key":"2026071419565929100_bnag005-B291","first-page":"3698","article-title":"Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma","volume":"62","author":"Schagdarsurengin","year":"2002","journal-title":"Cancer Res"},{"issue":"9","key":"2026071419565929100_bnag005-B292","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/labinvest.3700306","article-title":"RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors","volume":"85","author":"Nakamura","year":"2005","journal-title":"Lab Invest"},{"issue":"9","key":"2026071419565929100_bnag005-B293","doi-asserted-by":"crossref","first-page":"16304","DOI":"10.1002\/jcp.28295","article-title":"Investigating the expression and promoter methylation of RET gene in patients with medullary thyroid cancer with unmutated RET","volume":"234","author":"Shakiba","year":"2019","journal-title":"J Cell Physiol"},{"issue":"35","key":"2026071419565929100_bnag005-B294","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1038\/onc.2011.556","article-title":"Sprouty1 is a candidate tumor-suppressor gene in medullary thyroid carcinoma","volume":"31","author":"Maci\u00e0","year":"2012","journal-title":"Oncogene"},{"issue":"3","key":"2026071419565929100_bnag005-B295","doi-asserted-by":"crossref","first-page":"171","DOI":"10.34172\/aim.2022.29","article-title":"Cpg island methylation of the Rap1Gap gene in medullary thyroid cancer","volume":"25","author":"Faam","year":"2022","journal-title":"Arch Iran Med"},{"issue":"4","key":"2026071419565929100_bnag005-B296","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1158\/0008-5472.CAN-09-2812","article-title":"Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors","volume":"70","author":"Zuo","year":"2010","journal-title":"Cancer Res"},{"issue":"2","key":"2026071419565929100_bnag005-B297","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s12020-014-0204-3","article-title":"Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation","volume":"47","author":"Puppin","year":"2014","journal-title":"Endocrine"},{"issue":"3","key":"2026071419565929100_bnag005-B298","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2174\/1574892811666160614115356","article-title":"Epigenetics in medullary thyroid cancer: from pathogenesis to targeted therapy","volume":"11","author":"Vitale","year":"2016","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"5","key":"2026071419565929100_bnag005-B299","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1210\/jc.2007-2696","article-title":"MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility","volume":"93","author":"Nikiforova","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026071419565929100_bnag005-B300","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.yexmp.2013.05.001","article-title":"Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma","volume":"95","author":"Hudson","year":"2013","journal-title":"Exp Mol Pathol"},{"issue":"21","key":"2026071419565929100_bnag005-B301","doi-asserted-by":"crossref","first-page":"30461","DOI":"10.18632\/oncotarget.8458","article-title":"MicroRNA-375\/SEC23A as biomarkers of the in vitro efficacy of vandetanib","volume":"7","author":"Lassalle","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"2026071419565929100_bnag005-B302","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.febslet.2014.03.002","article-title":"MiR-129-5p is down-regulated and involved in the growth, apoptosis and migration of medullary thyroid carcinoma cells through targeting RET","volume":"588","author":"Duan","year":"2014","journal-title":"FEBS Lett"},{"issue":"1","key":"2026071419565929100_bnag005-B303","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12943-016-0563-x","article-title":"MiR-182 promotes cancer invasion by linking RET oncogene activated NF-\u03baB to loss of the HES1\/Notch1 regulatory circuit","volume":"16","author":"Spitschak","year":"2017","journal-title":"Mol Cancer"},{"key":"2026071419565929100_bnag005-B304","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.humpath.2018.05.019","article-title":"Evaluation of miRNAs expression in medullary thyroid carcinoma tissue samples: miR-34a and miR-144 as promising overexpressed markers in MTC","volume":"79","author":"Shabani","year":"2018","journal-title":"Hum Pathol"},{"issue":"2","key":"2026071419565929100_bnag005-B305","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/jcp.29055","article-title":"An investigation on the expression of miRNAs including miR-144 and miR-34a in plasma samples of RET-positive and RET-negative medullar thyroid carcinoma patients","volume":"235","author":"Shabani","year":"2020","journal-title":"J Cell Physiol"},{"issue":"1","key":"2026071419565929100_bnag005-B306","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3390\/cancers16010234","article-title":"MALAT-1 is a key regulator of epithelial-mesenchymal transition in cancer: a potential therapeutic target for metastasis","volume":"16","author":"Hussein","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2026071419565929100_bnag005-B307","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.yexmp.2017.10.002","article-title":"MicroRNA-21 and long non-coding RNA MALAT1 are overexpressed markers in medullary thyroid carcinoma","volume":"103","author":"Chu","year":"2017","journal-title":"Exp Mol Pathol"},{"issue":"1","key":"2026071419565929100_bnag005-B308","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13023-020-01665-5","article-title":"RMRP, RMST, FTX and IPW: novel potential long non-coding RNAs in medullary thyroid cancer","volume":"16","author":"Luz\u00f3n-Toro","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"2026071419565929100_bnag005-B309","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.3390\/ijms22115640","article-title":"Current advances on the important roles of enhancer RNAs in molecular pathways of cancer","volume":"22","author":"Wang","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2026071419565929100_bnag005-B310","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2174\/0115680096258716231026063704","article-title":"LINC00887 acts as an enhancer RNA to promote medullary thyroid carcinoma progression by binding with FOXQ1","volume":"24","author":"Liu","year":"2024","journal-title":"Curr Cancer Drug Targets"},{"issue":"17","key":"2026071419565929100_bnag005-B311","doi-asserted-by":"crossref","first-page":"28650","DOI":"10.18632\/oncotarget.15622","article-title":"Expression of HIF-1\u03b1 in medullary thyroid cancer identifies a subgroup with poor prognosis","volume":"8","author":"Lodewijk","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"2026071419565929100_bnag005-B312","doi-asserted-by":"crossref","first-page":"e12021","DOI":"10.1002\/ccs3.12021","article-title":"LncRNA ZFAS1 promotes invasion of medullary thyroid carcinoma by enhancing EPAS1 expression via miR-214-3p\/UCHL1 axis","volume":"18","author":"Chen","year":"2024","journal-title":"J Cell Commun Signal"},{"issue":"16","key":"2026071419565929100_bnag005-B313","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.3346\/jkms.2025.40.e56","article-title":"Comprehensive classification of surgically resected pituitary neuroendocrine tumors: updates from a single-institution experience based on the WHO 5th edition","volume":"40","author":"Kim","year":"2025","journal-title":"J Korean Med Sci"},{"key":"2026071419565929100_bnag005-B314","doi-asserted-by":"crossref","first-page":"152398","DOI":"10.1016\/j.anndiagpath.2024.152398","article-title":"PIT-1\/SF-1 co-expression in pituitary neuroendocrine tumors (PitNETs) with comprehensive review of the literature: how should we best characterize these neoplasms?","volume":"74","author":"Faraj","year":"2025","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"2026071419565929100_bnag005-B315","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","article-title":"Pangenomic classification of pituitary neuroendocrine tumors","volume":"37","author":"Neou","year":"2020","journal-title":"Cancer Cell"},{"issue":"1","key":"2026071419565929100_bnag005-B316","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000514862","article-title":"Pituitary tumors: genetic and molecular factors underlying pathogenesis and clinical behavior","volume":"112","author":"Spada","year":"2022","journal-title":"Neuroendocrinology"},{"issue":"6","key":"2026071419565929100_bnag005-B317","doi-asserted-by":"crossref","first-page":"R235","DOI":"10.1530\/EJE-19-0602","article-title":"Somatic and germline mutations in the pathogenesis of pituitary adenomas","volume":"181","author":"Vandeva","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026071419565929100_bnag005-B318","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1210\/clinem\/dgac703","article-title":"Integrating methylome and transcriptome signatures expands the molecular classification of the pituitary tumors","volume":"108","author":"Silva-J\u00fanior","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026071419565929100_bnag005-B319","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa156","article-title":"Demethylation status of somatic DNA extracted from pituitary neuroendocrine tumors indicates proliferative behavior","volume":"105","author":"Szab\u00f3","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026071419565929100_bnag005-B320","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.mce.2017.07.011","article-title":"Epigenetics of pituitary tumors: pathogenetic and therapeutic implications","volume":"469","author":"Ezzat","year":"2018","journal-title":"Mol Cell Endocrinol"},{"issue":"1-2","key":"2026071419565929100_bnag005-B321","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.mce.2013.09.006","article-title":"Genetic and epigenetic mutations of tumor suppressive genes in sporadic pituitary adenoma","volume":"386","author":"Zhou","year":"2014","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"2026071419565929100_bnag005-B322","doi-asserted-by":"crossref","first-page":"115584","DOI":"10.1016\/j.celrep.2025.115584","article-title":"Immune atlas of pituitary neuroendocrine tumors highlights endocrine-driven immune signature and therapeutic implication","volume":"44","author":"Guo","year":"2025","journal-title":"Cell Rep"},{"issue":"17","key":"2026071419565929100_bnag005-B323","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1158\/1078-0432.CCR-17-2206","article-title":"The epigenomic landscape of pituitary adenomas reveals specific alterations and differentiates among acromegaly, Cushing's disease and endocrine-inactive subtypes","volume":"24","author":"Salomon","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2026071419565929100_bnag005-B324","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.2353\/ajpath.2009.081131","article-title":"The expression of AIP-related molecules in elucidation of cellular pathways in pituitary adenomas","volume":"175","author":"Heli\u00f6vaara","year":"2009","journal-title":"Am J Pathol"},{"issue":"4","key":"2026071419565929100_bnag005-B325","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1210\/jc.2018-01856","article-title":"DNA methylation of tumor suppressor genes in pituitary neuroendocrine tumors","volume":"104","author":"Garc\u00eda-Mart\u00ednez","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026071419565929100_bnag005-B326","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noae148","article-title":"Developmental pluripotency-associated 4 increases aggressiveness of pituitary neuroendocrine tumors by enhancing cell stemness","volume":"27","author":"Chaudhary","year":"2025","journal-title":"Neuro Oncol"},{"issue":"8","key":"2026071419565929100_bnag005-B327","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/neuonc\/noab044","article-title":"DNA methylation-based signatures classify sporadic pituitary tumors according to clinicopathological features","volume":"23","author":"Mosella","year":"2021","journal-title":"Neuro Oncol"},{"issue":"3","key":"2026071419565929100_bnag005-B328","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s13167-021-00246-1","article-title":"Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies","volume":"12","author":"Aydin","year":"2021","journal-title":"EPMA J"},{"issue":"7","key":"2026071419565929100_bnag005-B329","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1128\/MCB.16.7.3245","article-title":"Site-specific methylation of the rat prolactin and growth hormone promoters correlates with gene expression","volume":"16","author":"Ng\u00f4","year":"1996","journal-title":"Mol Cell Biol"},{"issue":"1","key":"2026071419565929100_bnag005-B330","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1530\/JME-10-0137","article-title":"GATA transcription factors regulate LH\u03b2 gene expression","volume":"47","author":"Lo","year":"2011","journal-title":"J Mol Endocrinol"},{"key":"2026071419565929100_bnag005-B331","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.mce.2016.07.010","article-title":"Epigenetic regulation of alternative promoters and enhancers in progenitor, immature, and mature gonadotrope cell lines","volume":"434","author":"Laverri\u00e8re","year":"2016","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"2026071419565929100_bnag005-B332","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/nan.12675","article-title":"Gonadotroph tumours with a low SF-1 labelling index are more likely to recur and are associated with enrichment of the PI3K-AKT pathway","volume":"47","author":"Hickman","year":"2021","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"2026071419565929100_bnag005-B333","doi-asserted-by":"crossref","first-page":"e12870","DOI":"10.1111\/nan.12870","article-title":"Unveiling the identities of null cell tumours: epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour\/adenoma classification","volume":"49","author":"Dottermusch","year":"2023","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2026071419565929100_bnag005-B334","doi-asserted-by":"crossref","first-page":"3730657","DOI":"10.1155\/2020\/3730657","article-title":"The search of miRNA related to invasive growth of nonfunctioning gonadotropic pituitary tumors","volume":"2020","author":"Boresowicz","year":"2020","journal-title":"Int J Endocrinol"},{"issue":"7","key":"2026071419565929100_bnag005-B335","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s40618-019-01178-4","article-title":"MicroRNAs expression in pituitary tumors: differences related to functional status, pathological features, and clinical behavior","volume":"43","author":"Vicchio","year":"2020","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2026071419565929100_bnag005-B336","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3390\/jcm9061838","article-title":"Differential expression of microRNAs in silent and functioning corticotroph tumors","volume":"9","author":"Garc\u00eda-Mart\u00ednez","year":"2020","journal-title":"J Clin Med"},{"issue":"10","key":"2026071419565929100_bnag005-B337","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1210\/jc.2007-2633","article-title":"Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3\/DLK1 locus in human clinically nonfunctioning pituitary adenomas","volume":"93","author":"Gejman","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026071419565929100_bnag005-B338","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1210\/jc.2004-1848","article-title":"Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors","volume":"90","author":"Zhao","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026071419565929100_bnag005-B339","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1210\/en.2009-0657","article-title":"Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions","volume":"151","author":"Zhang","year":"2010","journal-title":"Endocrinology"},{"key":"2026071419565929100_bnag005-B340","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2015.08.018","article-title":"Tumor suppression by MEG3 lncRNA in a human pituitary tumor derived cell line","volume":"416","author":"Chunharojrith","year":"2015","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"2026071419565929100_bnag005-B341","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3171\/2019.10.JNS191959","article-title":"MEG3\/MIR-376B-3P\/HMGA2 axis is involved in pituitary tumor invasiveness","volume":"134","author":"Zhu","year":"2021","journal-title":"J Neurosurg"},{"issue":"4","key":"2026071419565929100_bnag005-B342","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3892\/or.2021.7991","article-title":"lncRNA MEG3 inhibits pituitary tumor development by participating in cell proliferation, apoptosis and EMT processes","volume":"45","author":"Wang","year":"2021","journal-title":"Oncol Rep"},{"issue":"23","key":"2026071419565929100_bnag005-B343","doi-asserted-by":"crossref","first-page":"5987","DOI":"10.3390\/cancers13235987","article-title":"The emerging role of non-coding RNAs in pituitary gland tumors and meningioma","volume":"13","author":"Ghafouri-Fard","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"17","key":"2026071419565929100_bnag005-B344","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2217\/epi-2021-0165","article-title":"The role of noncoding RNAs in pituitary adenoma","volume":"13","author":"Bahreini","year":"2021","journal-title":"Epigenomics"},{"issue":"3","key":"2026071419565929100_bnag005-B345","first-page":"3495","article-title":"MEG3 is associated with gsp oncogene regulation of growth hormone hypersecretion, proliferation and invasiveness of human GH-secreting adenomas","volume":"17","author":"Tang","year":"2019","journal-title":"Oncol Lett"},{"issue":"6","key":"2026071419565929100_bnag005-B346","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3390\/cancers13061395","article-title":"Large scale molecular studies of pituitary neuroendocrine tumors: novel markers, mechanisms and translational perspectives","volume":"13","author":"Peculis","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2026071419565929100_bnag005-B347","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3390\/cancers12020514","article-title":"How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020","volume":"12","author":"Trouillas","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026071419565929100_bnag005-B348","doi-asserted-by":"crossref","first-page":"924942","DOI":"10.3389\/fendo.2022.924942","article-title":"Architects of pituitary tumour growth","volume":"13","author":"Sabatino","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2026071419565929100_bnag005-B349","doi-asserted-by":"crossref","first-page":"e13302","DOI":"10.1111\/bpa.13302","article-title":"The 2022 WHO classification of tumors of the pituitary gland: an update on aggressive and metastatic pituitary neuroendocrine tumors","volume":"35","author":"Casar-Borota","year":"2025","journal-title":"Brain Pathol"},{"issue":"1","key":"2026071419565929100_bnag005-B350","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12022-021-09663-4","article-title":"Genomics and epigenomics of pituitary tumors: what do pathologists need to know?","volume":"32","author":"Asa","year":"2021","journal-title":"Endocr Pathol"},{"key":"2026071419565929100_bnag005-B351","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.12659\/MSM.910608","article-title":"Overexpression of DNA (Cytosine-5)-methyltransferase 1 (DNMT1) and DNA (Cytosine-5)-methyltransferase 3A (DNMT3A) is associated with aggressive behavior and hypermethylation of tumor suppressor genes in human pituitary adenomas","volume":"24","author":"Ma","year":"2018","journal-title":"Med Sci Monit"},{"issue":"21","key":"2026071419565929100_bnag005-B352","doi-asserted-by":"crossref","first-page":"15719","DOI":"10.3390\/ijms242115719","article-title":"Aggressive PitNETs and potential target therapies: a systematic review of molecular and genetic pathways","volume":"24","author":"Serioli","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026071419565929100_bnag005-B353","doi-asserted-by":"crossref","first-page":"841118","DOI":"10.3389\/fendo.2022.841118","article-title":"Methylome analysis in nonfunctioning and GH-secreting pituitary adenomas","volume":"13","author":"Giuffrida","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2026071419565929100_bnag005-B354","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/cen.14827","article-title":"Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients","volume":"97","author":"Guaraldi","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2026071419565929100_bnag005-B355","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00401-024-02836-5","article-title":"Genome-wide methylation profiling differentiates benign from aggressive and metastatic pituitary neuroendocrine tumors","volume":"148","author":"Jotanovic","year":"2024","journal-title":"Acta Neuropathol"},{"issue":"2","key":"2026071419565929100_bnag005-B356","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/gcc.20621","article-title":"Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas","volume":"48","author":"Kirsch","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"issue":"34","key":"2026071419565929100_bnag005-B357","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1038\/onc.2011.557","article-title":"Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis","volume":"31","author":"Palmieri","year":"2012","journal-title":"Oncogene"},{"issue":"1-2","key":"2026071419565929100_bnag005-B358","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.mce.2010.03.019","article-title":"HMGA2: a pituitary tumour subtype-specific oncogene?","volume":"326","author":"Fedele","year":"2010","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"2026071419565929100_bnag005-B359","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ccr.2006.04.024","article-title":"HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity","volume":"9","author":"Fedele","year":"2006","journal-title":"Cancer Cell"},{"issue":"5","key":"2026071419565929100_bnag005-B360","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1080\/15384101.2017.1403682","article-title":"HMGA2 cooperates with either p27","volume":"17","author":"Fedele","year":"2018","journal-title":"Cell Cycle"},{"key":"2026071419565929100_bnag005-B361","first-page":"39","article-title":"Epigenetic mechanisms leading to overexpression of HMGA proteins in human pituitary adenomas","volume":"2","author":"D'Angelo","year":"2015","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"2026071419565929100_bnag005-B362","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1007\/s11033-023-08523-0","article-title":"Differential expression levels of \u03b2-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET)","volume":"50","author":"Taghavi","year":"2023","journal-title":"Mol Biol Rep"},{"issue":"3","key":"2026071419565929100_bnag005-B363","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11102-008-0147-x","article-title":"Pituitary gland and beta-catenin signaling: from ontogeny to oncogenesis","volume":"12","author":"Gueorguiev","year":"2009","journal-title":"Pituitary"},{"issue":"1","key":"2026071419565929100_bnag005-B364","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/1097-0142(20010101)91:1<42::AID-CNCR6>3.0.CO;2-7","article-title":"Frequent nuclear accumulation of beta-catenin in pituitary adenoma","volume":"91","author":"Semba","year":"2001","journal-title":"Cancer"},{"issue":"1","key":"2026071419565929100_bnag005-B365","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s40478-022-01441-5","article-title":"Phosphorylation of \u03b2-catenin at Serine552 correlates with invasion and recurrence of non-functioning pituitary neuroendocrine tumours","volume":"10","author":"Rai","year":"2022","journal-title":"Acta Neuropathol Commun"},{"issue":"10","key":"2026071419565929100_bnag005-B366","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1210\/en.2011-1216","article-title":"Inactivation of PITX2 transcription factor induced apoptosis of gonadotroph tumoral cells","volume":"152","author":"Acunzo","year":"2011","journal-title":"Endocrinology"},{"issue":"11","key":"2026071419565929100_bnag005-B367","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1007\/s00018-021-03833-7","article-title":"Pitx genes in development and disease","volume":"78","author":"Tran","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"2026071419565929100_bnag005-B368","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.anndiagpath.2018.10.003","article-title":"Gene and protein expression of E-cadherin and NCAM markers in non-functioning pituitary adenomas","volume":"38","author":"Ongaratti","year":"2019","journal-title":"Ann Diagn Pathol"},{"issue":"20","key":"2026071419565929100_bnag005-B369","doi-asserted-by":"crossref","first-page":"9043","DOI":"10.18632\/aging.102372","article-title":"T5224, RSPO2 and AZD5363 are novel drugs against functional pituitary adenoma","volume":"11","author":"Zhong","year":"2019","journal-title":"Aging (Albany NY)"},{"issue":"12","key":"2026071419565929100_bnag005-B370","doi-asserted-by":"crossref","first-page":"e13052","DOI":"10.1111\/jne.13052","article-title":"The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours","volume":"33","author":"Marques","year":"2021","journal-title":"J Neuroendocrinol"},{"issue":"6","key":"2026071419565929100_bnag005-B371","doi-asserted-by":"crossref","first-page":"R45\u2013","DOI":"10.1093\/ejendo\/lvaf100","article-title":"Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas","volume":"192","author":"Raverot","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026071419565929100_bnag005-B372","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3390\/ijms26020531","article-title":"DNA methylation in pituitary adenomas: a scoping review","volume":"26","author":"M\u00f8ller","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2026071419565929100_bnag005-B373","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.3390\/ijms23095122","article-title":"Circulating noncoding RNAs in pituitary neuroendocrine tumors-two sides of the same coin","volume":"23","author":"Butz","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2026071419565929100_bnag005-B374","first-page":"55","article-title":"MicroRNAs as potential biomarkers in pituitary adenomas","volume":"7","author":"Donati","year":"2021","journal-title":"Noncoding RNA"},{"issue":"6","key":"2026071419565929100_bnag005-B375","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s11596-022-2673-6","article-title":"Overview of the 2022 WHO classification of pituitary adenomas\/pituitary neuroendocrine tumors: clinical practices, controversies, and perspectives","volume":"42","author":"Wan","year":"2022","journal-title":"Curr Med Sci"},{"issue":"1","key":"2026071419565929100_bnag005-B376","doi-asserted-by":"crossref","first-page":"278","DOI":"10.7150\/thno.77918","article-title":"Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models","volume":"13","author":"Ullrich","year":"2023","journal-title":"Theranostics"},{"issue":"2","key":"2026071419565929100_bnag005-B377","first-page":"95","article-title":"Azacytidine induces cell cycle arrest and suppression of neuroendocrine markers in carcinoids","volume":"3","author":"Alexander","year":"2010","journal-title":"Int J Clin Exp Med"},{"issue":"15","key":"2026071419565929100_bnag005-B378","first-page":"5905","article-title":"Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors","volume":"61","author":"Lubomierski","year":"2001","journal-title":"Cancer Res"},{"issue":"9","key":"2026071419565929100_bnag005-B379","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.2967\/jnumed.118.224048","article-title":"Combination of 5-fluorouracil with epigenetic modifiers induces radiosensitization, somatostatin receptor 2 expression, and radioligand binding in neuroendocrine tumor cells in vitro","volume":"60","author":"Jin","year":"2019","journal-title":"J Nucl Med"},{"issue":"19","key":"2026071419565929100_bnag005-B380","doi-asserted-by":"crossref","first-page":"14791","DOI":"10.18632\/oncotarget.9462","article-title":"Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells","volume":"9","author":"Veenstra","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"2026071419565929100_bnag005-B381","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.surg.2022.12.008","article-title":"Novel treatment strategy of targeting epigenetic dysregulation in pancreatic neuroendocrine tumors","volume":"173","author":"Zhu","year":"2023","journal-title":"Surgery"},{"issue":"5","key":"2026071419565929100_bnag005-B382","doi-asserted-by":"crossref","first-page":"336","DOI":"10.2174\/138920209788920994","article-title":"Potential of DNMT and its epigenetic regulation for lung cancer therapy","volume":"10","author":"Tang","year":"2009","journal-title":"Curr Genomics"},{"key":"2026071419565929100_bnag005-B383","doi-asserted-by":"crossref","first-page":"875122","DOI":"10.3389\/fonc.2022.875122","article-title":"High histone deacetylase 2\/3 expression in non-functioning pituitary tumors","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"2026071419565929100_bnag005-B384","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2217\/epi-2023-0142","article-title":"Role of epigenetic drugs in sensitizing cancers to anticancer therapies: emerging trends and clinical advancements","volume":"15","author":"Singh","year":"2023","journal-title":"Epigenomics"},{"issue":"1","key":"2026071419565929100_bnag005-B385","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/1471-2407-10-383","article-title":"Cell type-specific anti-cancer properties of valproic acid: independent effects on HDAC activity and Erk1\/2 phosphorylation","volume":"10","author":"Gotfryd","year":"2010","journal-title":"BMC Cancer"},{"issue":"4","key":"2026071419565929100_bnag005-B386","doi-asserted-by":"crossref","first-page":"e90458","DOI":"10.1371\/journal.pone.0090458","article-title":"High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paraganglioma","volume":"9","author":"Giubellino","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"2026071419565929100_bnag005-B387","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.surg.2008.08.027","article-title":"Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells","volume":"144","author":"Adler","year":"2008","journal-title":"Surgery"},{"issue":"7","key":"2026071419565929100_bnag005-B388","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/s41588-018-0138-4","article-title":"A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors","volume":"50","author":"Alvarez","year":"2018","journal-title":"Nat Genet"},{"issue":"4","key":"2026071419565929100_bnag005-B389","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1677\/erc.1.01249","article-title":"Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells","volume":"13","author":"Baradari","year":"2006","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"2026071419565929100_bnag005-B390","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.3390\/ijms19103128","article-title":"Pharmacological inhibition of class IIA HDACs by LMK-235 in pancreatic neuroendocrine tumor cells","volume":"19","author":"Wanek","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2026071419565929100_bnag005-B391","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/pmic.200600811","article-title":"Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A","volume":"7","author":"Cecconi","year":"2007","journal-title":"Proteomics"},{"issue":"6","key":"2026071419565929100_bnag005-B392","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.3390\/cells10061408","article-title":"Targeting HDACs in pancreatic neuroendocrine tumor models","volume":"10","author":"Schmitz","year":"2021","journal-title":"Cells"},{"issue":"2","key":"2026071419565929100_bnag005-B393","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/1061186X.2015.1066794","article-title":"Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II","volume":"24","author":"Sun","year":"2016","journal-title":"J Drug Target"},{"issue":"8","key":"2026071419565929100_bnag005-B394","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1159\/000545073","article-title":"Upregulation of SSTR2 expression and radioligand binding of [18F]SiTATE in neuroendocrine tumour cells with combined inhibition of class I HDACs and LSD1","volume":"115","author":"Auernhammer","year":"2025","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2026071419565929100_bnag005-B395","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.surg.2019.05.092","article-title":"Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment","volume":"167","author":"Guenter","year":"2020","journal-title":"Surgery"},{"issue":"6","key":"2026071419565929100_bnag005-B396","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3390\/cancers11060767","article-title":"Pulmonary carcinoid surface receptor modulation using histone deacetylase inhibitors","volume":"11","author":"Guenter","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2026071419565929100_bnag005-B397","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1158\/1535-7163.MCT-07-2140","article-title":"Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model","volume":"7","author":"Miyanaga","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2026071419565929100_bnag005-B398","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.tranon.2019.11.001","article-title":"Inhibition of HDAC6 attenuates tumor growth of non-small cell lung cancer","volume":"13","author":"Deskin","year":"2020","journal-title":"Transl Oncol"},{"issue":"2","key":"2026071419565929100_bnag005-B399","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jss.2008.08.004","article-title":"Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride","volume":"159","author":"Adler","year":"2010","journal-title":"J Surg Res"},{"issue":"8","key":"2026071419565929100_bnag005-B400","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1210\/jc.2017-00464","article-title":"Histone deacetylase inhibitor SAHA is a promising treatment of Cushing disease","volume":"102","author":"Lu","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026071419565929100_bnag005-B401","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40478-024-01775-2","article-title":"Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors","volume":"12","author":"Cheng","year":"2024","journal-title":"Acta Neuropathol Commun"},{"issue":"8","key":"2026071419565929100_bnag005-B402","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1210\/en.2012-1231","article-title":"Epigenomic silencing of the BMP-4 gene in pituitary adenomas: a potential target for epidrug-induced re-expression","volume":"153","author":"Yacqub-Usman","year":"2012","journal-title":"Endocrinology"},{"issue":"7","key":"2026071419565929100_bnag005-B403","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/2159-8290.CD-11-0214","article-title":"Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer","volume":"1","author":"Juergens","year":"2011","journal-title":"Cancer Discov"},{"issue":"4","key":"2026071419565929100_bnag005-B404","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nrendo.2018.3","article-title":"Current and emerging therapies for PNETs in patients with or without MEN1","volume":"14","author":"Frost","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"2026071419565929100_bnag005-B405","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.canlet.2017.02.021","article-title":"Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer","volume":"394","author":"Leal","year":"2017","journal-title":"Cancer Lett"},{"issue":"5","key":"2026071419565929100_bnag005-B406","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1038\/oncsis.2017.30","article-title":"Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors","volume":"6","author":"Lines","year":"2017","journal-title":"Oncogenesis"},{"issue":"11","key":"2026071419565929100_bnag005-B407","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1158\/0008-5472.CAN-12-3292","article-title":"PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains","volume":"73","author":"Picaud","year":"2013","journal-title":"Cancer Res"},{"issue":"10","key":"2026071419565929100_bnag005-B408","doi-asserted-by":"crossref","first-page":"e1450","DOI":"10.1038\/cddis.2014.396","article-title":"The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors","volume":"5","author":"Wong","year":"2014","journal-title":"Cell Death Dis"},{"issue":"3","key":"2026071419565929100_bnag005-B409","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1530\/ERC-19-0448","article-title":"Effects of epigenetic pathway inhibitors on corticotroph tumour AtT20 cells","volume":"27","author":"Lines","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"16","key":"2026071419565929100_bnag005-B410","doi-asserted-by":"crossref","first-page":"e122225","DOI":"10.1172\/jci.insight.122225","article-title":"Transcriptional targeting of oncogene addiction in medullary thyroid cancer","volume":"3","author":"Valenciaga","year":"2018","journal-title":"JCI Insight"},{"issue":"2","key":"2026071419565929100_bnag005-B411","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1158\/1078-0432.CCR-22-2168","article-title":"A phase II trial of guadecitabine in children and adults with SDH-deficient GIST, pheochromocytoma, paraganglioma, and HLRCC-associated renal cell carcinoma","volume":"29","author":"Ligon","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2026071419565929100_bnag005-B412","doi-asserted-by":"crossref","first-page":"817-e1213","DOI":"10.1093\/oncolo\/oyae118","article-title":"Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors","volume":"29","author":"Jamison","year":"2024","journal-title":"Oncologist"},{"issue":"8","key":"2026071419565929100_bnag005-B413","first-page":"632","article-title":"Potential for increasing uptake of radiolabeled 68Ga-DOTATOC and 123I-MIBG in patients with midgut neuroendocrine tumors using a histone deacetylase inhibitor vorinostat","volume":"36","author":"Pollard","year":"2021","journal-title":"Cancer Biother Radiopharm"},{"issue":"7","key":"2026071419565929100_bnag005-B414","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1634\/theoncologist.2016-0060","article-title":"A phase II trial of a histone deacetylase inhibitor panobinostat in patients with low-grade neuroendocrine tumors","volume":"21","author":"Jin","year":"2016","journal-title":"Oncologist"},{"issue":"6","key":"2026071419565929100_bnag005-B415","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1634\/theoncologist.2011-0031","article-title":"A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma","volume":"16","author":"Mohammed","year":"2011","journal-title":"Oncologist"},{"issue":"13","key":"2026071419565929100_bnag005-B416","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1158\/1078-0432.CCR-05-2689","article-title":"Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors","volume":"12","author":"Shah","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2026071419565929100_bnag005-B417","doi-asserted-by":"crossref","first-page":"e957","DOI":"10.1002\/ctm2.957","article-title":"Effect of epigenetic treatment on SST(2) expression in neuroendocrine tumour patients","volume":"12","author":"Refardt","year":"2022","journal-title":"Clin Transl Med"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnag005\/66931028\/bnag005.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/47\/4\/422\/66931028\/bnag005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/47\/4\/422\/66931028\/bnag005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:58:10Z","timestamp":1784073490000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/47\/4\/422\/8487348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":417,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2,16]]},"published-print":{"date-parts":[[2026,7,15]]}},"URL":"https:\/\/doi.org\/10.1210\/endrev\/bnag005","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,2,16]]}}}